Document and Entity Information (USD $)	12 Months Ended
Document and Entity Information (USD $)	Dec. 31, 2011	Feb. 21, 2012	Jun. 30, 2011
Entity Information [Line Items]
Entity Registrant Name	MERIT MEDICAL SYSTEMS INC
Entity Central Index Key	0000856982
Document Type	10-K
Document Period End Date	Dec. 31, 2011
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Public Float			$ 711,681,890
Entity Common Stock, Shares Outstanding		41,999,063
Document Fiscal Year Focus	2011
Document Fiscal Period Focus	FY

CONSOLIDATED BALANCE SHEETS (USD $) In Thousands, unless otherwise specified	Dec. 31, 2011	Dec. 31, 2010
CURRENT ASSETS:
Cash and cash equivalents	$ 10,128	$ 3,735
Trade receivables - net of allowances for uncollectible accounts - 2011 - $464 and 2010 - $593	40,550	37,362
Employee receivables	154	110
Other receivables	1,750	1,242
Inventories	69,911	60,597
Prepaid expenses and other assets	3,775	2,089
Prepaid income taxes	883	452
Deferred income tax assets	3,704	4,647
Income tax refund receivable	2,797	2,067
Total current assets	133,652	112,301
PROPERTY AND EQUIPMENT:
Land and land improvements	16,288	12,586
Buildings	59,905	50,274
Manufacturing equipment	103,629	92,839
Furniture and fixtures	22,559	18,313
Leasehold improvements	12,659	12,121
Construction-in-progress	47,534	13,775
Total property and equipment	262,574	199,908
Less accumulated depreciation	(83,434)	(71,853)
Property and equipment-net	179,140	128,055
OTHER ASSETS:
Developed technology — net of accumulated amortization — 2011 — $4,759 and 2010—$2,301	35,415	34,273
Other - net of accumulated amortization - 2011-$10,215 and 2010 - $6,695	21,254	22,911
Goodwill	61,144	58,675
Deferred income tax assets	5,366	4,140
Marketable securities	2,798	0
Other assets	8,248	9,125
Total other assets	134,225	129,124
TOTAL	447,017	369,480
CURRENT LIABILITIES:
Trade payables	22,727	20,092
Accrued expenses	20,197	18,890
Advances from employees	225	307
Income taxes payable	646	887
Total current liabilities	43,795	40,176
LONG-TERM DEBT	30,737	81,538
DEFERRED INCOME TAX LIABILITIES	2,112	1,267
LIABILITIES RELATED TO UNRECOGNIZED TAX BENEFITS	3,489	3,527
DEFERRED COMPENSATION PAYABLE	4,585	4,258
DEFERRED CREDITS	1,984	1,763
OTHER LONG-TERM OBLIGATIONS	3,226	1,336
Total liabilities	89,928	133,865
COMMITMENTS AND CONTINGENCIES (Notes 2, 7, 8, 9 and 13)
STOCKHOLDERS' EQUITY:
Preferred stock-5,000 shares authorized as of December 31, 2011 and 2010; no shares issued
Common stock, no par value; shares authorized — 2011 and 2010 - 100,000; issued shares as of December 31, 2011 - 42,008 and December 31, 2010 - 35,496	166,231	67,091
Retained earnings	190,708	167,664
Accumulated other comprehensive income	150	860
Total stockholders' equity	357,089	235,615
TOTAL	$ 447,017	$ 369,480

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $) In Thousands, unless otherwise specified	Dec. 31, 2011	Dec. 31, 2010
CURRENT ASSTS:
Trade receivables, allowances (in dollars)	$ 464	$ 593
OTHER ASSETS:
Intangibles, accumulated amortization (in dollars)	10,215	6,695
Developed Technology accumulated amortization	$ 4,759	$ 2,301
STOCKHOLDERS' EQUITY:
Preferred stock, shares authorized	5,000	5,000
Preferred stock, shares issued	0	0
Common stock, shares authorized	100,000	100,000
Common stock, shares issued	42,008	35,496

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $) In Thousands, except Per Share data, unless otherwise specified	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
NET SALES	$ 359,449	$ 296,755	$ 257,462
COST OF SALES	193,981	168,257	148,660
GROSS PROFIT	165,468	128,498	108,802
OPERATING EXPENSES:
Selling, general, and administrative	104,502	87,615	64,787
Research and development	21,938	15,335	11,168
Acquired in-process research and development	5,838	0	0
Goodwill, Impairment Loss	0	8,344	0
Total operating expenses	132,278	111,294	75,955
INCOME FROM OPERATIONS	33,190	17,204	32,847
OTHER INCOME (EXPENSE):
Interest income	129	34	178
Interest expense	(789)	(596)	(28)
Other income	345	146	97
Other income (expense) - net	(315)	(416)	247
INCOME BEFORE INCOME TAXES	32,875	16,788	33,094
INCOME TAX EXPENSE	9,831	4,328	10,564
Net Income	$ 23,044	$ 12,460	$ 22,530
EARNINGS PER COMMON SHARE:
Earnings Per Share, Basic	$ 0.59	$ 0.35	$ 0.64
Diluted (in dollars per share)	$ 0.58	$ 0.35	$ 0.63
AVERAGE COMMON SHARES:
Basic (in shares)	39,086	35,290	35,014
Diluted (in shares)	39,733	35,976	35,758

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (USD $) In Thousands, except Share data, unless otherwise specified	Total	Accumulated Other Comprehensive Income (Loss) [Member]	Common Stock [Member]	Retained Earnings [Member]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest at Dec. 31, 2008	$ 194,305	$ (58)	$ 61,689	$ 132,674
Common Stock, Shares, Outstanding at Dec. 31, 2008			35,116,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Income	22,530			22,530
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax	(27)	(27)
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest	22,503
Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation	987		987
Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition	1,182		1,182
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period			385,000
Stock Issued During Period, Value, Employee Stock Purchase Plan	353		353
Stock Issued During Period, Shares, Other			64,000
Stock Issued During Period, Value, Other	517		517
Stock Issued During Period, Value, Stock Options Exercised	1,920		1,920
Stock Issued During Period, Shares, Employee Stock Purchase Plans			30,000
Stock Repurchased and Retired During Period, Value	(2,474)		(2,474)
Stock Repurchased and Retired During Period, Shares			(313,000)
Stock Surrendered During Period Value Payroll Tax Liabilities Stock Options Exercised	(254)		(254)
Stock Surrendered During Period Shares Payroll Tax Liabilities Stock Options Exercised			(29,000)
Stock Surrendered During Period Value Stock Options Exercised	(230)		(230)
Stock Surrendered During Period Shares Stock Options Exercised	(27,000)		(27,000)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest at Dec. 31, 2009	218,809	(85)	63,690	155,204
Common Stock, Shares, Outstanding at Dec. 31, 2009			35,226,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Income	12,460			12,460
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Net of Tax	708	708
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax	237	237
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest	13,405
Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation	399		399
Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition	1,294		1,294
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period			239,000
Stock Issued During Period, Value, Employee Stock Purchase Plan	378		378
Stock Issued During Period, Value, Stock Options Exercised	1,330		1,330
Stock Issued During Period, Shares, Employee Stock Purchase Plans			31,000
Stock Surrendered During Period Value Stock Options Exercised	0
Stock Surrendered During Period Shares Stock Options Exercised	0
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest at Dec. 31, 2010	235,615	860	67,091	167,664
Common Stock, Shares, Outstanding at Dec. 31, 2010			35,496,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Income	23,044			23,044
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Net of Tax	(708)	(708)
Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax	180	180
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax	(182)	(182)
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest	22,334
Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation	3,122		3,122
Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition	1,644		1,644
Stock Issued During Period, Value, New Issues	87,700		87,700
Stock Issued During Period, Shares, New Issues	5,520,000		5,520,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	(1,099,000)		1,099,000
Stock Issued During Period, Value, Employee Stock Purchase Plan	430		430
Stock Issued During Period, Value, Stock Options Exercised	8,449		8,449
Stock Issued During Period, Shares, Employee Stock Purchase Plans			31,000
Stock Surrendered During Period Value Payroll Tax Liabilities Stock Options Exercised	(953)		(953)
Stock Surrendered During Period Shares Payroll Tax Liabilities Stock Options Exercised			(60,000)
Stock Surrendered During Period Value Stock Options Exercised	(1,252)		(1,252)
Stock Surrendered During Period Shares Stock Options Exercised	(78,000)		(78,000)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest at Dec. 31, 2011	$ 357,089	$ 150	$ 166,231	$ 190,708
Common Stock, Shares, Outstanding at Dec. 31, 2011			42,008,000

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (Parentheticals) (USD $)	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010
Interest rate swap, net of tax	$ 451,000	$ 451,000
Unrealized gain on marketable securities, net of tax	$ 115,000

- Definition

Tax effect of the gross appreciation or the gross loss, net of reclassification adjustment, in the value of the total unsold available-for-sale securities at the end of an accounting period.

+ References+ Details

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Income	$ 23,044	$ 12,460	$ 22,530
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	19,194	14,856	12,271
Losses on sales and/or abandonment of property and equipment	31	533	271
Write-off of certain patents and license agreement	103	134	154
Goodwill, Impairment Loss	0	8,344	0
Acquired in-process research and development	5,838	0	0
Amortization of deferred credits	(106)	(111)	(120)
Purchase of trading investments	0	(644)	(458)
Unrealized (gains) losses on trading investments	0	(382)	(561)
Deferred income taxes	1,677	(554)	1,791
Tax benefit attributable to appreciation of common stock options exercised	(3,122)	(399)	(987)
Stock-based compensation expense	1,644	1,294	1,182
Changes in operating assets and liabilities, net of effects from acquisitions:
Trade receivables	(3,323)	(2,088)	(2,131)
Employee receivables	(62)	29	(16)
Other receivables	(245)	223	(13)
Inventories	(9,314)	(7,614)	(6,882)
Prepaid expenses and other assets	(1,726)	(192)	(571)
Prepaid income taxes	(431)	(60)	0
Income tax refund receivable	(733)	(1,573)	319
Other assets	(283)	(43)	(568)
Trade payables	(2,129)	5,643	296
Accrued expenses	1,334	3,090	1,628
Advances from employees	(65)	99	0
Income taxes payable	2,658	1,037	825
Non-current liabilities related to unrecognized tax benefits	(226)	(372)	114
Deferred compensation payable	327	876	1,034
Other long-term obligations	(70)	174	(38)
Total adjustments	10,971	22,300	7,540
Net cash provided by operating activities	34,015	34,760	30,070
Capital expenditures for:
Property and equipment	(59,195)	(23,648)	(18,478)
Patents and trademarks	(2,077)	(1,083)	(1,191)
Purchase of marketable securities	(2,503)	0	0
Proceeds from the sale of marketable securities	0	9,673	0
Proceeds from the sale of property and equipment	5	17	27
Cash paid in acquisitions, net of cash acquired	(10,250)	(97,785)	(46,150)
Net cash used in investing activities	(74,020)	(112,826)	(65,792)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock	95,454	1,708	2,560
Payments of Stock Issuance Costs	(127)	0	0
Proceeds from issuance of long-term debt	104,585	108,491	0
Payments on long-term debt	(155,386)	(26,953)	0
Borrowings on line of credit	0	1,500	19,000
Payments on line of credit	0	(8,500)	(12,000)
Excess tax benefits from stock-based compensation	3,122	399	987
Long-term debt issuance costs	0	(522)	0
Payment of taxes related to an exchange of common stock	(953)	0	(254)
Common stock repurchased and retired	0	0	(2,474)
Net cash provided by financing activities	46,695	76,123	7,819
EFFECT OF EXCHANGE RATES ON CASH	(297)	(455)	6
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	6,393	(2,398)	(27,897)
CASH AND CASH EQUIVALENTS:
Beginning of year	3,735	6,133	34,030
End of year	10,128	3,735	6,133
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION-Cash paid during the period (net capitalized interest of $264 and $0, respectively):
Interest	509	512	26
Income taxes	7,023	6,050	8,215
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES
Property and equipment purchases in accounts payable	8,849	3,778	2,724
Acquisition purchases in accounts payable	1,270	250	0
Merit common stock surrendered (78, 0 and 27 shares) in exchange for exercise of stock options	$ 1,252	$ 0	$ 230

CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) (USD $) In Thousands, except Share data, unless otherwise specified	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
net capitalized interest	$ 299	$ 13	$ 0
Company's common stock surrendered in exchange for the exercise of stock options (in shares)	78,000	0	27,000

Organization And Summary Of Significant Accounting Policies

12 Months Ended

Dec. 31, 2011

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization and Summary of Significant Accounting Policies

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Organization. Merit Medical Systems, Inc. (“Merit,” “we” or “us,”) designs, develops, manufactures and markets single-use medical products for interventional and diagnostic procedures. For financial reporting purposes, we report our operations in two operating segments: cardiovascular and endoscopy. Our cardiovascular segment consists of cardiology and radiology devices which assist in diagnosing and treating coronary arterial disease, peripheral vascular disease and other non-vascular diseases and includes the embolotherapeutic products we acquired through our acquisition of BioSphere Medical, Inc. (“BioSphere”) as described in Note 2 below. Our endoscopy segment consists of gastroenterology and pulmonology medical devices which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures caused by malignant tumors.

We manufacture our products in plants located in the United States, The Netherlands, Ireland and France. We export sales to dealers and have direct sales forces in the United States, Western Europe and China (see Note 12). Our consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. The following is a summary of the more significant of such policies.

Use of Estimates in Preparing Financial Statements. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Principles of Consolidation. The consolidated financial statements include our wholly-owned subsidiaries. Intercompany balances and transactions have been eliminated.

Cash and Cash Equivalents. For purposes of the statements of cash flows, we consider interest bearing deposits with an original maturity date of three months or less to be cash equivalents.

Receivables. The allowance for uncollectible accounts receivable is based on our historical bad debt experience and on management’s evaluation of our ability to collect individual outstanding balances.

Inventories. We value our inventories at the lower of cost, determined on a first-in, first-out method, or market value. Market value for raw materials is based on replacement costs. Inventory costs include material, labor and manufacturing overhead. We review inventories on hand at least quarterly and record provisions for estimated excess, slow moving and obsolete inventory, as well as inventory with a carrying value in excess of net realizable value. The regular and systematic inventory valuation reviews include a current assessment of future product demand, historical experience and product expiration.

Goodwill and Intangible Assets. We test goodwill balances as of July 1 for impairment on an annual basis during the third quarter, or whenever impairment indicators arise. We utilize several reporting units in evaluating goodwill for impairment. We assess the estimated fair value of reporting units based on discounted future cash flows. If the carrying amount of a reporting unit exceeds the fair value of the reporting unit, an impairment charge is recognized in an amount equal to the excess of the carrying amount of the reporting unit goodwill over the implied fair value of that goodwill.

We evaluate the recoverability of intangible assets periodically and take into account events or circumstances that warrant revised estimates of useful lives or that indicate that impairment exists. All of our intangible assets are subject to amortization. Intangible assets are amortized on a straight-line basis, except for customer lists, which are generally amortized on an accelerated basis, over the following useful lives:



Customer lists	5	-	15 years
Developed technology	5	-	15 years
Distribution agreements	5	-	11 years
License agreements and trademarks	5	-	15 years
Covenant not to compete	3	-	10 years
Patents	17 years
Royalty agreements	5 years

Long-Lived Assets. We periodically review the carrying amount of our long-lived assets for impairment. An asset is considered impaired when estimated future cash flows are less than the carrying amount of the asset. In the event the carrying amount of such asset is not considered recoverable, the asset is adjusted to its fair value. Fair value is generally determined based on discounted future cash flow. There were no impairments of long-lived assets during the years ended December 31, 2011, 2010 and 2009.

Property and Equipment. Property and equipment is stated at the historical cost of construction or purchase. Construction costs include interest costs capitalized during construction. Maintenance and repairs of property and equipment are charged to operations as incurred. Leasehold improvements are amortized over the lesser of the base term of the lease or estimated life of the leasehold improvements. Construction-in-process consists of new buildings and various production equipment being constructed internally and externally. Assets in construction-in-process will commence depreciating once the asset has been placed in service. Depreciation is computed using the straight-line method over estimated useful lives as follows:



Buildings	40 years
Manufacturing equipment	4	-	20 years
Furniture and fixtures	3	-	10 years
Land improvements	10	-	20 years
Leasehold improvements	4	-	25 years

Depreciation expense related to property and equipment for the years ended December 31, 2011, 2010 and 2009 was approximately $13.2 million, $11.4 million, and $10.0 million, respectively.

Deferred Compensation. We have a deferred compensation plan that permits certain management employees to defer a portion of their salary until the future. We established a Rabbi trust to finance obligations under the plan with corporate-owned variable life insurance contracts. The cash surrender value totaled approximately $4.8 million and $4.3 million at December 31, 2011 and 2010, respectively, which is included in other assets in our consolidated balance sheets. We have recorded a deferred compensation payable of approximately $4.6 million and $4.3 million at December 31, 2011 and 2010, respectively, to reflect the liability to our employees under this plan.

Marketable Securities. Marketable securities consist entirely of available-for-sale equity securities. As of December 31, 2011, these equity securities had a cost basis of approximately $2.5 million, fair value of approximately $2.8 million, and gross unrealized gains that are included in accumulated other comprehensive income of approximately $295,000. There were no gross unrealized losses as of December 31, 2011.

Other Assets. As of December 31, 2011, other assets consisted of our deferred compensation plan cash surrender value discussed above, an investment in a privately-held company accounted for at cost, deposits related to various leases, unamortized debt issuance costs and a long-term income tax refund receivable. As of December 31, 2010, other assets also included the fair value of an interest rate swap.

Deferred Credits. Deferred credits consist of grant money received from the Irish government. Grant money is received for a percentage of expenditures on eligible property and equipment, specific research and development projects and costs of hiring and training employees. Amounts related to the acquisition of property and equipment are amortized as a reduction of depreciation expense over the lives of the corresponding property and equipment.

Revenue Recognition. We sell our single-use disposable medical products through a direct sales force in the U.S., through OEM relationships, custom procedure tray manufacturers and a combination of direct sales force and independent distributors in international markets. Revenues from these customers are recognized when all of the following have occurred: (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been rendered, (iii) the price is fixed or determinable and (iv) the ability to collect is reasonably assured. These criteria are generally satisfied at the time of shipment when risk of loss and title passes to the customer. We have certain written agreements with group purchasing organizations to sell our products to participating hospitals. These agreements have destination shipping terms which require us to defer the recognition of a sale until the product has arrived at the participating hospitals. We reserve for sales returns of defective products (i.e. warranty liability) as a reduction in revenue, based on our historical experience. We also offer sales rebates and discounts to purchasing groups. These reserves are recorded as a reduction in revenue and are not considered material to our consolidated statements of income for the years ended December 31, 2011, 2010 and 2009. In addition, we invoice our customers for taxes assessed by governmental authorities such as sales tax and value added taxes. We present these taxes on a net basis.

Shipping and Handling. We bill our customers for shipping and handling charges, which are included in total revenues for the applicable period and the corresponding shipping and handling expense is reported in cost of goods sold.

Cost of Sales. We include product costs (i.e. material, direct labor and overhead costs), shipping and handling expense, product royalty expense, developed technology expense, production-related depreciation expense and product license agreement expense in cost of goods sold.

Research and Development. Research and development costs are expensed as incurred.

Income Taxes. We utilize an asset and liability approach for financial accounting and reporting for income taxes. Deferred income taxes are provided for temporary differences in the basis of assets and liabilities as reported for financial statement and income tax purposes. Deferred income taxes reflect the tax effects of net operating loss and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of certain deferred tax assets is dependent upon future earnings, if any. We make estimates and judgments in determining the need for a provision for income taxes, including the estimation of our taxable income for each full fiscal year.

Earnings per Common Share. Net income per common share is computed by both the basic method, which uses the weighted average number of our common shares outstanding and the diluted method, which includes the dilutive common shares from stock options and warrants, as calculated using the treasury stock method.

Fair Value Measurements. The fair value of a financial instrument is the amount that could be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Financial assets are marked to bid prices and financial liabilities are marked to offer prices. Fair value measurements do not include transaction costs. A fair value hierarchy is used to prioritize the quality and reliability of the information used to determine fair values. Categorization within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. The fair value hierarchy is defined into the following three categories:

Level 1: Quoted market prices in active markets for identical assets or liabilities.

Level 2: Observable market-based inputs or inputs that are corroborated by market data.

Level 3: Unobservable inputs that are not corroborated by market data.

Stock-Based Compensation. We recognize the fair value compensation cost relating to share-based payment transactions in accordance with Accounting Standards Codification (“ASC”) 718, Compensation — Stock Compensation. Under the provisions of ASC 718, share-based compensation cost is measured at the grant date, based on the fair value of the award and is recognized over the employee’s requisite service period, which is generally the vesting period. The fair value of our stock options is estimated using a Black-Scholes option valuation model. Stock-based compensation expense for the years ended December 31, 2011, 2010 and 2009 was approximately $1.6 million, $1.3 million and $1.2 million, respectively.

Concentration of Credit Risk. Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. We provide credit, in the normal course of business, primarily to hospitals and independent third-party custom procedure tray manufacturers and distributors. We perform ongoing credit evaluations of our customers and maintain allowances for potential credit losses. Sales to our single largest customer approximated 4%, 4% and 6% of total sales for the years ended December 31, 2011, 2010 and 2009, respectively.

Foreign Currency. The financial statements of our foreign subsidiaries are measured using local currencies as the functional currency, with the exception of Ireland which uses the U.S. Dollar as its functional currency. Assets and liabilities are translated into U.S. Dollars at year-end rates of exchange and results of operations are translated at average rates for the year. Gains and losses resulting from these translations are included in accumulated other comprehensive loss as a separate component of stockholders’ equity. Foreign currency transactions denominated in a currency other than the entity’s functional currency are included in determining net income for the period. Such foreign currency transaction gains and losses have not been significant for purposes of our financial reporting.

Derivatives. We use forward contracts to mitigate our exposure to volatility in foreign exchange rates, and we used an interest rate swap to hedge changes in the benchmark interest rate related to our Credit Agreement described in Note 7 below. All derivatives are recognized in the consolidated balance sheets at fair value. Classification of each hedging instrument is based upon whether the maturity of the instrument is less than or greater than 12 months. We do not purchase or hold derivative financial instruments for speculative or trading purposes. See Note 8.

Accumulated Other Comprehensive Income (Loss). As of December 31, 2011, accumulated other comprehensive income (loss) included approximately $180,000 (net of tax of $115,000) related to unrealized gains on marketable securities and $(30,000) related to foreign currency translation. As of December 31, 2010, accumulated other comprehensive income included approximately $708,000 (net of tax of $451,000) related to an interest rate swap and $152,000 related to foreign currency translation.

Recently Issued Financial Accounting Standards. In September 2011, the Financial Accounting Standards Board (“FASB”) issued authoritative guidance related to testing goodwill for impairment. This guidance provides that entities may first assess qualitative factors to determine whether it is necessary to perform the two-step goodwill impairment test. If the qualitative assessment results in a more than 50% likely result that the fair value of a reporting unit is less than the carrying amount, then the entity must continue to apply the two-step impairment test. If the entity concludes the fair value exceeds the carrying amount, then neither of the two steps in the goodwill impairment test is required. This guidance is effective for annual and interim goodwill impairment tests performed for fiscal years beginning after December 15, 2011 with early adoption permitted. We are currently evaluating the impact of adopting this guidance on our consolidated financial statements.

In June 2011, the FASB issued authoritative guidance on the presentation of comprehensive income. This guidance specifies that an entity has the option to present the total of comprehensive income, the components of net income, and the components of other comprehensive income either in a single continuous statement of comprehensive income or in two separate but consecutive statements. In both choices, an entity is required to present each component of net income along with total net income, each component of other comprehensive income along with a total for other comprehensive income, and a total amount for comprehensive income. This guidance does not change the items that must be reported in other comprehensive income or when an item of other comprehensive income must be reclassified to net income. It also does not change the presentation of related tax effects, before related tax effects, or the portrayal or calculation of earnings per share. This guidance is to be applied retrospectively and is effective for fiscal years, and interim periods within those years, beginning after December 15, 2011. We are currently evaluating the impact of adopting this guidance on our consolidated financial statements.

In December 2010, the FASB issued authoritative guidance which modifies the requirements of step one of the goodwill impairment test for reporting units with zero or negative carrying amounts. This guidance modifies step one so that for those reporting units, an entity is required to perform step two of the goodwill impairment test if it is more likely than not that a goodwill impairment exists. In determining whether it is more likely than not that a goodwill impairment exists, an entity should consider whether there are any adverse qualitative factors indicating that an impairment may exist. We adopted this guidance during the year ended December 31, 2011, the adoption of which did not have a material effect on our consolidated financial statements.

In October 2009, the FASB issued authoritative guidance that addresses whether multiple deliverables exist, how the deliverables should be separated and how the consideration should be allocated to one or more units of accounting. This guidance establishes a selling price hierarchy for determining the selling price of a deliverable. The selling price used for each deliverable will be based on vendor-specific objective evidence, if available, third-party evidence if vendor-specific objective evidence is not available, or estimated selling price if neither vendor-specific nor third-party evidence is available. We adopted this guidance prospectively for revenue arrangements entered into or materially modified after January 1, 2011, the adoption of which did not have a material effect on our consolidated financial statements.

- Definition

The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.

+ References+ Details

Acquisitions

12 Months Ended

Dec. 31, 2011

Business Combinations [Abstract]

Acquisitions

ACQUISITIONS

On September 2, 2011, we entered into an Asset Purchase Agreement with Ash Access Technology, Inc. (“Ash Access”), an Indiana corporation, and AAT Catheter Technologies, LLC (“AAT”), an Indiana limited liability corporation (collectively “Ash”), to purchase intellectual property rights with respect to various dialysis catheters. We made an initial payment of $5.0 million to Ash in September 2011. We are obligated to pay an additional $1.0 million upon reaching a certain milestone set forth in the purchase agreement and future royalties based on a percentage of related product sales. We accounted for this acquisition as a business combination. The acquisition-date fair value of these contingent liabilities has been included as part of the purchase consideration. Acquisition-related costs during the year ended December 31, 2011, respectively, which are included in selling, general and administrative expense in the accompanying consolidated statements of operations, were not material. During the year ended December 31, 2011, sales subsequent to the acquisition date related to our dialysis catheter acquired were not material. The purchase price was preliminarily allocated as follows (in thousands):



Assets Acquired
Property and equipment	$	73
Intangibles
Developed technology	3,200
Customer lists	300
Goodwill	2,697
Total assets acquired	6,270

Liabilities Assumed
Contingent liabilities	1,270

Net assets acquired	$	5,000

With respect to the assets we acquired from Ash, we intend to amortize developed technology over 15 years and customer lists on an accelerated basis over two years. The total weighted-average amortization period for these acquired intangible assets is nine years. The assets and liabilities related to this acquisition are included in our cardiovascular segment.

Pro forma consolidated financial results for the Ash acquisition discussed above have not been included in our consolidated financial results because we believe their effects would not be material.

On June 20, 2011, we acquired the intellectual property rights to certain vena cava filter technology. We made an initial payment of $1.0 million in June 2011, and we are obligated to pay up to an additional $3.5 million if certain milestones set forth in the agreement are reached related to further research and development activities and regulatory approval of the vena cava filter.

On July 18, 2011, we acquired the intellectual property rights to certain introducer sheath technology. We made an initial payment of $1.0 million in July 2011, and we are obligated to pay an additional $1.0 million upon the earlier of the commercialization of the product or the third anniversary of the effective date of the agreement. The discounted liability of $948,000 has been reflected in our consolidated balance sheets as a long-term liability as of December 31, 2011.

On December 15, 2011, we acquired the intellectual property rights to certain support guide catheter technology. We made an initial payment of $2.0 million in December 2011, and we are obligated to pay up to an additional $3.0 million if certain obligations and milestones set forth in the agreement are performed or reached related to further research and development activities and regulatory approval of the support guide catheter.

Each of these three transactions discussed above represented an asset acquisition related to a research and development project and a not business combinations. A total charge of approximately $4.9 million related to these acquired in-process research and development assets has been included in the accompanying consolidated statements of operations for the year ended December 31, 2011, since technological feasibility of the underlying research and development projects had not yet been reached and such technology had no future alternative use.

On September 10, 2010, we completed our acquisition of BioSphere in an all-cash merger transaction valued at approximately $95.7 million, inclusive of all common equity and Series A Preferred preferences. BioSphere develops and markets embolotherapeutic products for the treatment of uterine fibroids, hypervascularized tumors and arteriovenous malformations. We believe the acquisition of BioSphere gives us a platform technology applicable to multiple therapeutic areas with significant market potential while leveraging existing interventional radiology call points. The gross amount of trade receivables we acquired from BioSphere was approximately $4.6 million, of which $51,000 was expected to be uncollectible. Our consolidated financial statements for the year ended December 31, 2010 reflect sales subsequent to the acquisition date of approximately $9.0 million related to our BioSphere acquisition. We report sales and operating expenses related to the BioSphere acquisition in our cardiovascular segment. It is not practical to separately report the earnings related to the BioSphere acquisition, as we cannot split out sales costs related to Biosphere’s products, principally because our sales representatives are selling multiple products (including BioSphere products) in the cardiovascular business segment. As of December 31, 2010, the BioSphere purchase price was allocated as follows (in thousands):



Assets Acquired
Marketable securities	$	9,673
Trade receivables	4,529
Inventories	5,694
Other assets	1,340
Property and equipment	546
Deferred income tax assets	16,012
Intangibles
Developed technology	19,000
Customer list	7,900
License agreement	380
Trademark	3,200
Goodwill	34,016
Total assets acquired	102,290

Liabilities Assumed
Accounts payable	322
Accrued expenses	3,617
Deferred income tax liabilities	729
Liabilities related to unrecognized tax benefits	961
Other liabilities	936
Total liabilities assumed	6,565

Net assets acquired, net of cash acquired of $274	$	95,725

During the year ended December 31, 2011, the goodwill related to the BioSphere acquisition was decreased by approximately $228,000. The change was primarily due to BioSphere tax adjustments including items related to the BioSphere 2010 income tax return, which was finalized during the third quarter of 2011.

With respect to the BioSphere assets, we intend to amortize developed technology over 15 years, a license agreement over 10 years and customer lists on an accelerated basis over 10 years. While U.S. trademarks can be renewed indefinitely, we currently estimate that we will generate cash flow from the acquired trademarks for a period of 15 years from the acquisition date. The total weighted-average amortization period for these acquired intangible assets is 13.6 years.

In connection with our BioSphere acquisition, we paid approximately $522,000 in long-term debt issuance costs to Wells Fargo Bank for our long-term debt (see Note 7). These costs consist primarily of loan origination fees and legal costs that we intend to amortize over five years, which is the contract term of our unsecured Credit Agreement, dated September 10, 2010 with Lenders who are or may become party thereto and Wells Fargo, as administrative agent for the Lenders. We also incurred approximately $86,000 and $2.5 million of acquisition-related costs during the years ended December 31, 2011 and 2010, respectively, which are included in selling, general and administrative expense in the accompanying consolidated statements of operations.

During the fourth quarter of 2010, we terminated several exclusive BioSphere sales distributor agreements in European countries where we already had previously established direct sales relationships. In connection with the termination of these agreements, we agreed to purchase customer lists from the terminated distributors. The total purchase price of the customer lists was approximately $1.3 million and was allocated to customer lists. We intend to amortize the customer lists on an accelerated basis over 10 years.

On February 19, 2010, we entered into a manufacturing and technology license agreement with a medical device manufacturer for certain medical products. We made an initial payment of $250,000 in February 2010, a second payment of $250,000 in May 2010, a third payment of $250,000 in November 2010 and a final payment of $250,000 in August 2011. We have included the $1.0 million intangible asset in developed technology and intend to amortize the asset over an estimated life of 10 years.

The following table summarizes our consolidated results of operations for the years ended December 31, 2010 and 2009, as well as the pro forma consolidated results of operations as though the BioSphere acquisition had occurred on January 1, 2009 (in thousands, except per share amounts):



	Year Ended December 31, 2010				Year Ended December 31, 2009
	As Reported		Pro Forma		As Reported		Pro Forma
Sales	$	296,755	$	317,382	$	257,462	$	288,589
Net income	12,460		7,258		22,530		17,000
Earnings per common share:
Basic	$	0.35	$	0.21	$	0.64	$	0.49
Diluted	$	0.35	$	0.20	$	0.63	$	0.48

The unaudited pro forma information set forth above is for informational purposes only and should not be considered indicative of actual results that would have been achieved if BioSphere had been acquired the beginning of 2009, or results that may be obtained in any future period.

On October 21, 2009, we entered into an Exclusive License, Development and Supply Agreement with Vysera Biomedical Limited (“Vysera”), pursuant to which Vysera granted to us an exclusive license to use, modify and sell certain valve technology and biomaterial coating technology for medical devices (the “Licensed Technology”) and other intellectual property associated with the Licensed Technology and to develop and market improvements to the Licensed Technology. In the transaction, we also purchased 253,047 A Ordinary Shares of Vysera, for an aggregate price of approximately $2.4 million. Under the License Agreement, we paid Vysera a license fee of $1.5 million and agreed to pay royalties on products we sell that incorporate the Licensed Technology. The license fee of $1.5 million has been allocated to developed technology, which we intend to amortize over 15 years. During 2011, we abandoned our Vysera coating technology of $500,000, which has been included in the accompanying consolidated statements of operations in acquired in-process research and development. On April 6, 2011, we supplemented and amended our Exclusive License, Development and Supply Agreement with Vysera to include the manufacturing rights for Vysera’s valve technology. We made an initial payment of $500,000 in April 2011 and a final payment of $500,000 in August of 2011. We have recorded the $1.0 million intangible asset as developed technology for purposes of our consolidated balance sheet and we intend to amortize it over an estimated life of 10 years.

On June 2, 2009, we entered into an Asset Purchase Agreement with Hatch Medical, L.L.C., a Georgia limited liability company (“Hatch”), to purchase assets associated with the EN Snare® foreign body retrieval system. We paid Hatch $21.0 million as of December 31, 2009. Our consolidated financial statements for the year ended December 31, 2009 reflect royalty income subsequent to the acquisition date of approximately $1.0 million and a net income of approximately $210,000 related to our Hatch acquisition. The purchase price was allocated as follows (in thousands):



Assets Acquired
Intangibles
Developed technology	$	8,100
Customer list	590
Non-compete	240
Trademark	650
Goodwill	11,420
Total assets acquired	21,000

Liabilities Assumed	—

Net assets acquired	$	21,000

With respect to the assets we acquired from Hatch, we are amortizing developed technology over 11 years and a non-compete covenant over seven years. The acquired trademarks are scheduled to renew in 3.87 years (based on a weighted-average computation, from December 31, 2009 until the trademark renewal date). While U.S. trademarks can be renewed indefinitely, we currently estimate that we will generate cash flow from the acquired trademarks for a period of 15 years from the acquisition date.

On February 18, 2009, we entered into an Asset Purchase Agreement with Alveolus to purchase their non-vascular interventional stents used for esophageal, tracheobronchial, and biliary stenting procedures. We paid Alveolus $19.1 million in March 2009. The gross amount of trade receivables we acquired from Alveolus is approximately $1.0 million, of which $49,000 was expected to be uncollectible. Our consolidated financial statements for the year ended December 31, 2009 reflect sales subsequent to the acquisition date of approximately $6.1 million and a net loss of approximately $2.3 million related to our acquisition of the Alveolus assets. The purchase price was allocated as follows (in thousands):



Assets Acquired
Inventories	$	1,741
Trade receivables	974
Other assets	241
Property and equipment	547
Intangibles
Developed technology	5,700
Trademarks	1,400
Customer lists	1,100
In-process research and development	400
Goodwill	8,028
Total assets acquired	20,131

Liabilities Assumed
Accounts payable	467
Other liabilities	572
Total liabilities assumed	1,039

Net assets acquired	$	19,092

With respect to the assets we acquired from Alveolus, we are amortizing the developed technology and trademarks over 15 years and customer lists on an accelerated basis over seven years. We intend to amortize the in-process research and development over 15 years, which will begin if the resulting product is successfully launched in the market. The acquired trademarks are scheduled to renew in 3.52 years (based on a weighted-average calculation, from December 31, 2009 until the trademark renewal date). While U.S. trademarks can be renewed indefinitely, we currently estimate that we will generate cash flow from the acquired trademarks for a period of 15 years from the acquisition date.

Our in-process research and development (“IPR&D”) intangible asset in the foregoing table represented the value of in-process projects acquired in 2009 that had not yet reached technological feasibility and had no alternative future uses as of the date of acquisition. The primary basis for determining the technological feasibility of these projects is obtaining regulatory approval to market the underlying products in an applicable geographic region. During 2011, we abandoned our IPR&D related to our covered biliary stent resulting in a charge of $400,000, which has been included in the accompanying consolidated statements of operations in acquired IPR&D.

On February 19, 2009, we entered into an Asset Purchase and Supply Agreement with Biosearch to purchase a bipolar coagulation probe and grafted biliary stents. We paid Biosearch $1.1 million in February 2009 and paid Biosearch an additional $500,000 in June 2009. Our consolidated financial statements for the year ended December 31, 2009 reflect sales subsequent to the acquisition date of approximately $1.6 million and net income of approximately $320,000 related to the Biosearch acquisition. The purchase price was allocated as follows (in thousands):



Assets Acquired
Inventories	$	188
Property and equipment	31
Intangibles
Developed technology	380
Customer lists	660
Non-compete	25
Goodwill	316
Total assets acquired	1,600

Liabilities Assumed	—

Net assets acquired	$	1,600

With respect to the assets we acquired from Biosearch, we are amortizing developed technology over 15 years, customer lists on an accelerated basis over eight years and a non-compete covenant over seven years.

The following table summarizes our consolidated results of operations for the year ended December 31, 2009, as well as the pro forma consolidated results of operations as though the Hatch, Alveolus and Biosearch transactions had occurred on January 1, 2009 (in thousands, except per share amounts):



	Year Ended December 31, 2009
	As Reported		Pro Forma
Sales	$	257,462	$	259,914
Net income	22,530		22,470
Earnings per common share:
Basic	$	0.64	$	0.64
Diluted	$	0.63	$	0.63

The goodwill arising from the acquisitions discussed above consists largely of the synergies and economies of scale we hope to achieve from combining the acquired assets and operations with our historical operations (see Note 4). The goodwill recognized from these acquisitions is expected to be deductible for income tax purposes, except for the goodwill recognized in connection with our stock acquisition of BioSphere.

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6909870&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6909870&loc=d3e1486-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4922-128472

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6909870&loc=d3e1392-128463

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6909870&loc=d3e1383-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4845-128472

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4934-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6911361&loc=d3e6996-128479

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6911361&loc=d3e7000-128479

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=6909870&loc=d3e1524-128463

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 88-16

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141

-Paragraph 51, 52

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141R

-Appendix F

-Paragraph F4

-Subparagraph e

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141R

-Paragraph 67-73

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6911361&loc=d3e6927-128479

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6909870&loc=d3e1490-128463

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6911361&loc=d3e7008-128479

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6909870&loc=d3e1500-128463

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4926-128472

+ Details

Inventories

12 Months Ended

Dec. 31, 2011

Inventory Disclosure [Abstract]

Inventories

INVENTORIES

Inventories at December 31, 2011 and 2010, consisted of the following (in thousands):



	2011		2010
Finished goods	$	38,095	$	30,780
Work-in-process	6,047		7,012
Raw materials	25,769		22,805

Total	$	69,911	$	60,597

- Definition

The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.

+ References+ Details

Goodwill and Intangible Assets

12 Months Ended

Dec. 31, 2011

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets

GOODWILL AND INTANGIBLE ASSETS

The changes in the carrying amount of goodwill for the years ended December 31, 2011 and 2010, are as follows (in thousands):



	2011			2010
Goodwill balance at January 1	$	58,675		$	33,002
Impairment charge	—			(8,343		)
Adjustment related to previous acquisitions	(228		)	—
Additions as the result of acquisitions	2,697			34,016
Goodwill balance at December 31	$	61,144		$	58,675

During our annual test of goodwill balances in 2010, which was completed during the third quarter, we determined that our goodwill related to our endoscopy reporting unit was impaired. We determined that, based on estimated future cash flows for this reporting unit, discounted back to their present value using a discount rate that reflects the risk profiles of the underlying activities, the carry value amount of this reporting unit was less than its estimated fair value. Some of the factors that influenced our estimated cash flows were slower sales growth in the products acquired from our Alveolus acquisition in March of 2009, uncertainty regarding acceptance of new products and continued operating losses in our endoscopy business segment. During the year ended December 31, 2010, we recorded an impairment charge of approximately $8.3 million, which was offset by approximately $3.2 million of deferred tax asset. As of December 31, 2011 and 2010, total accumulated goodwill impairment loss was approximately $8.3 million, all of which is related to the endoscopy segment.

Other intangible assets at December 31, 2011 and 2010, consisted of the following (in thousands):



	2011
	Gross					Net
	Carrying Amount		Accumulated Amortization			Carrying Amount
Patents	$	6,455	$	(1,704	)	$	4,751
Distribution agreement	2,426		(900		)	1,526
License agreements	1,983		(436		)	1,547
Trademark	5,746		(1,014		)	4,732
Covenant not to compete	315		(108		)	207
Customer lists	14,277		(5,786		)	8,491
Royalty agreements	267		(267		)	—

Total	$	31,469	$	(10,215	)	$	21,254



	2010
	Gross					Net
	Carrying Amount		Accumulated Amortization			Carrying Amount
Patents	$	4,631	$	(1,445	)	$	3,186
Distribution agreement	2,426		(641		)	1,785
License agreements	1,833		(352		)	1,481
Trademark	5,761		(636		)	5,125
In-process research and development	400		—			400
Covenant not to compete	315		(67		)	248
Customer lists	13,973		(3,287		)	10,686
Royalty agreements	267		(267		)	—

Total	$	29,606	$	(6,695	)	$	22,911

Aggregate amortization expense for the years ended December 31, 2011, 2010 and 2009 was approximately $6.0 million, $3.5 million and $2.3 million, respectively.

Estimated amortization expense for the intangible assets for the next five years consists of the following as of December 31, 2011 (in thousands):



Year Ending December 31
2012	$	5,767
2013	5,550
2014	5,090
2015	4,818
2016	4,811

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References+ Details

Income Taxes

12 Months Ended

Dec. 31, 2011

Income Tax Disclosure [Abstract]

Income Taxes

INCOME TAXES

For the years ended December 31, 2011, 2010 and 2009, income before income taxes is broken out between U.S. and foreign-sourced operations and consisted of the following (in thousands):



	2011		2010		2009
Domestic	$	21,123	$	10,551	$	26,918
Foreign	11,752		6,237		6,176

Total	$	32,875	$	16,788	$	33,094

The components of the provision for income taxes for the years ended December 31, 2011, 2010 and 2009 consisted of the following (in thousands):



	2011		2010			2009

Current expense:
Federal	$	5,662	$	3,547		$	7,846
State	1,001		595			689
Foreign	1,491		740			238

Total current expense	8,154		4,882			8,773

Deferred expense (benefit):
Federal	1,121		30			1,264
State	74		(545		)	227
Foreign	482		(39		)	300

Total deferred expense (benefit)	1,677		(554		)	1,791

Total	$	9,831	$	4,328		$	10,564

The difference between the income tax expense reported and amounts computed by applying the statutory federal rate of 35.0% to pretax income for the years ended December 31, 2011, 2010 and 2009 consisted of the following (in thousands):



	2011			2010			2009

Computed federal income tax expense at statutory rate of 35%	$	11,506		$	5,876		$	11,583
State income taxes	699			33			596
Tax credits	(778		)	(530		)	(670		)
Production activity deduction	(425		)	(355		)	(215		)
Foreign tax rate differential	(1,297		)	(1,212		)	(1,062		)
Uncertain tax positions	281			(372		)	114
Deferred compensation insurance assets	88			(133		)	(196		)
Transaction-related expenses	—			323			—
Other — including the effect of graduated rates	(243		)	698			414

Total income tax expense	$	9,831		$	4,328		$	10,564

Deferred income tax assets and liabilities at December 31, 2011 and 2010, consisted of the following temporary differences and carry-forward items (in thousands):



	2011			2010

Deferred income tax assets:
Allowance for uncollectible accounts receivable	$	188		$	242
Accrued compensation expense	3,064			3,230
Inventory differences	364			1,796
Net operating loss carry-forwards	22,689			26,273
Deferred revenue	273			214
Stock-based compensation expense	2,166			1,923
Uncertain tax positions	1,052			577
Other	1,848			1,686
Total deferred income tax assets	31,644			35,941

Deferred income tax liabilities:
Prepaid expenses	(823		)	(493		)
Property and equipment	(17,236		)	(18,103		)
Intangible assets	(6,169		)	(9,320		)
Other	(97		)	(505		)
Total deferred income tax liabilities	(24,325		)	(28,421		)
Valuation allowance	(361		)	—
Net deferred income tax assets	$	6,958		$	7,520

Reported as:
Deferred income tax assets - Current	$	3,704		$	4,647
Deferred income tax assets - Long-term	5,366			4,140
Deferred income tax liabilities - Current	—			—
Deferred income tax liabilities - Long-term	(2,112		)	(1,267		)

Net deferred income tax assets	$	6,958		$	7,520

The long-term deferred income tax balances are not netted as they represent deferred amounts applicable to different taxing jurisdictions. Deferred income tax balances reflect the temporary differences between the carrying amounts of assets and liabilities and their tax bases and are stated at enacted tax rates expected to be in effect when taxes are actually paid or recovered. The valuation allowance is primarily related to state credit carryforwards for which we believe it is more likely than not that the deferred tax asset will not be realized.

We have not provided U.S. deferred income taxes or foreign withholding taxes on the undistributed earnings of certain foreign subsidiaries that are intended to be reinvested indefinitely in operations outside the United States. It is not practical to estimate the amount of additional taxes that might be payable on such undistributed earnings.

As of December 31, 2011 and 2010, we had U.S federal net operating loss carryforwards of approximately $64.6 million and $72.4 million, respectively, which were generated by BioSphere prior to our acquisition of BioSphere in September 2010. These net operating loss carryforwards, which expire at various dates through 2030, are subject to an annual limitation under Internal Revenue Code Section 382. We anticipate that we will utilize the net operating loss carryforwards over the next fifteen years. During 2011 and 2010, we utilized approximately $8.6 million and $2.6 million, respectively, in U.S. federal net operating loss carryforwards.

As of December 31, 2011 and 2010, we had non-U.S. net operating loss carryforwards of approximately $250,000 and $2.8 million, respectively, which had no expiration date. During 2011, we utilized approximately $2.6 million in non-U.S. net operating loss carryforwards.

We are subject to income taxes in the United States and numerous foreign jurisdictions. Significant judgment is required in determining our worldwide provision for income taxes and recording the related assets and liabilities. In the ordinary course of our business, there are many transactions and calculations where the ultimate tax determination is uncertain. In our opinion, we have made adequate provisions for income taxes for all years subject to audit. Our U.S. federal tax returns for the 2009 tax year are currently under examination by the United States Internal Revenue Service (the “IRS”). We are no longer subject to U.S. federal, state, and local income tax examinations by tax authorities for years before 2007. In foreign jurisdictions, we are no longer subject to income tax examinations for years before 2006.

Although we believe our estimates are reasonable, the final outcomes of these matters may be different from those which we have reflected in our historical income tax provisions and accruals. Such differences could have a material effect on our income tax provision and operating results in the period in which we make such determination.

The total liability for unrecognized tax benefits at December 31, 2011 and 2010, including temporary tax differences, was approximately $3.5 million and $3.5 million, respectively, of which approximately $2.4 million and $2.9 million, respectively, would favorably impact our effective tax rate if recognized. As of December 31, 2011 and 2010, we have accrued approximately $376,000 and $651,000 respectively, in total interest and penalties related to unrecognized tax benefits. We account for interest and penalties for unrecognized tax benefits as part of our income tax provision. During the years ended December 31, 2011, 2010 and 2009, we added interest and penalties of approximately $12,000, $400,000 and $9,000, respectively, to our liability for unrecognized tax benefits. We do not anticipate that unrecognized tax benefits will significantly increase or decrease within 12 months of the reporting date.

A reconciliation of the beginning and ending amount of liabilities associated with uncertain tax positions for the years ended December 31, 2011, 2010 and 2009 consisted of the following (in thousands):



Tabular Roll-forward	2011			2010			2009

Unrecognized tax benefits, opening balance	$	2,952		$	2,790		$	2,668
Gross increases in tax positions taken in a prior year	347			518			163
Gross decreases in tax positions taken in a prior year	—			(51		)	(40		)
Gross increases in tax positions taken in the current year	865			520			710
Settlements with taxing authorities	(507		)	—			—
Lapse of applicable statute of limitations	(544		)	(825		)	(711		)
Unrecognized tax benefits, ending balance	$	3,113		$	2,952		$	2,790

The tabular roll-forward ending balance does not include interest and penalties related to unrecognized tax benefits. During the year ended December 31, 2011, we paid approximately $507,000 to the IRS in order to settle a withholding tax issue related to our acquisition of BioSphere. The payment of the withholding tax did not have a material impact on our consolidated financial statements for the year ended December 31, 2011, as the tax liability had been identified as part of our acquisition accounting of BioSphere and recorded in our consolidated financial statements.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 136, 172

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 43, 44, 45, 46, 47, 48, 49

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

+ Details

Revolving Credit Facility and Long-Term Debt	12 Months Ended
Revolving Credit Facility and Long-Term Debt	Dec. 31, 2011
Debt Disclosure [Abstract]
Revolving Credit Facility and Long-Term Debt	REVOLVING CREDIT FACILITY AND LONG-TERM DEBT We entered into the Credit Agreement with the Lenders and Wells Fargo, as administrative agent for the Lenders. Pursuant to the terms of the Credit Agreement, the Lenders have agreed to make revolving credit loans up to an aggregate amount of $125 million. Wells Fargo has also agreed to make swingline loans from time to time through the maturity date of September 10, 2015 in amounts equal to the difference between the amounts actually loaned by the Lenders and the aggregate credit commitment. On September 10, 2015, all principal, interest and other amounts outstanding under the Credit Agreement are payable in full. At any time prior to the maturity date, we may repay any amounts owing under all revolving credit loans and all swingline loans in whole or in part, without premium or penalty. Revolving credit loans made under the Credit Agreement bear interest, at our election, at either (i) the base rate (described below) plus 0.25%, (ii) the London Inter-Bank Offered Rate (“LIBOR”) Market Index Rate (as defined in the Credit Agreement) plus 1.25%, or (iii) the LIBOR Rate (as defined in the Credit Agreement) plus 1.25%. Swingline loans bear interest at the LIBOR Market Index Rate plus 1.25%. Interest on each loan featuring the base rate or the LIBOR Market Index Rate is due and payable on the last business day of each calendar month; interest on each loan featuring the LIBOR Rate is due and payable on the last day of each interest period selected by us when selecting the LIBOR Rate as the benchmark for interest calculation. For purposes of the Credit Agreement, the base rate means the highest of (i) the prime rate (as announced by Wells Fargo), (ii) the federal funds rate plus 0.50%, and (iii) LIBOR for an interest period of one month plus 1.00%. The Credit Agreement contains covenants, representations and warranties and other terms, that are customary for revolving credit facilities of this nature. In this regard, the Credit Agreement requires us to maintain a leverage ratio and EBITDA ratio, consolidated net income, and limits the amount of annual capital expenditures. Additionally, the Credit Agreement contains various negative covenants with which we must comply, including, but not limited to, a prohibition on the payment of dividends and limitations respecting: the incurrence of indebtedness, the creation of liens on our property, mergers or similar combinations or liquidations, asset dispositions, investments in subsidiaries, and other provisions customary in similar types of agreements. As of December 31, 2011, we were in compliance with all financial debt covenants set forth in the Credit Agreement. As of December 31, 2011, we had outstanding borrowings of approximately $30.7 million under the Credit Agreement, with available borrowings of approximately $94.3 million, based on the leverage ratio in the terms of the Credit Agreement. Our interest rate as of December 31, 2011 was a fixed rate of 1.54% on $24.0 million, a fixed rate of 1.55% on $5.0 million and a variable floating rate of 1.84% on approximately $1.7 million. Our interest rate as of December 31, 2010 was a fixed rate of 2.73% on $55.0 million as a result of an interest rate swap (see Note 8), a fixed rate of 1.52% on $22.0 million and a variable floating rate of 1.56% on approximately $4.5 million. On December 7, 2006, we entered into an unsecured loan agreement with Bank of America, whereby Bank of America agreed to provide us with a line of credit in the amount of $30.0 million, which expired on December 7, 2010. The loan agreement required us to pay interest at a rate equal to the lesser of (i) the maximum lawful rate of interest permitted under applicable usury laws, or (ii) Bank of America’s prime rate, plus a negative margin, as defined in the loan agreement. Alternatively, we could elect optional interest rates based on LIBOR during interest periods we agreed to with Bank of America. During the year ended December 31, 2010, all outstanding amounts were repaid and the loan agreement was terminated in September 2010.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References+ Details

Derivatives	12 Months Ended
Derivatives	Dec. 31, 2011
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives	DERIVATIVES General. Our earnings and cash flows are subject to fluctuations due to changes in interest rates and foreign currency exchange rates, and we seek to mitigate a portion of these risks by entering into derivative contracts. The derivatives we use are an interest rate swap and forward contracts. We recognize derivatives as either assets or liabilities at fair value in the accompanying consolidated balance sheets, regardless of whether or not hedge accounting is applied. We report cash flows arising from our hedging instruments consistent with the classification of cash flows from the underlying hedged items. Accordingly, cash flows associated with our derivative programs are classified as operating activities in the accompanying consolidated statements of cash flows. We formally document, designate and assess the effectiveness of transactions that receive hedge accounting initially and on an ongoing basis. Changes in the fair value of derivatives that qualify for hedge accounting treatment are recorded, net of applicable taxes, in accumulated other comprehensive income (loss), a component of stockholders’ equity in the accompanying consolidated balance sheets. For the ineffective portions of qualifying hedges, the change in fair value is recorded through earnings in the period of change. Changes in the fair value of derivatives not designated as cash flow hedges are recorded in earnings throughout the term of the derivative instrument. Interest Rate Swap. A portion of our debt bears interest at variable interest rates and therefore, we are subject to variability in the cash paid for interest expense. In order to mitigate a portion of this risk, we used a hedging strategy to reduce the variability of cash flows in the interest payments associated with the first $55 million of the total variable-rate debt outstanding under our Credit Agreement that was solely due to changes in the benchmark interest rate. This strategy allowed us to fix a portion of our interest payments. On October 25, 2010, we entered into a $55 million pay-fixed, receive-variable interest rate swap with Wells Fargo at a fixed interest rate of 2.73%. The variable portion of the interest rate swap was tied to the one-month LIBOR rate (the benchmark interest rate). The interest rates under both the interest rate swap and the underlying debt reset, the swap was settled with the counterparty, and interest was paid, on a monthly basis. The interest rate swap was scheduled to expire on September 10, 2015. This interest rate swap qualified as a cash flow hedge. At December 31, 2010, the interest rate swap qualified as a cash flow hedge. The fair value of our interest rate swap at December 31, 2010 was approximately $1.2 million, which was offset by approximately $451,000 of deferred tax liability. On July 7, 2011, we terminated our interest rate swap agreement, which resulted in a cash receipt of and gain of approximately $28,000 upon final settlement. During the years ended December 31, 2011 and 2010, the amount reclassified from accumulated other comprehensive income to earnings due to hedge effectiveness was approximately $73,000 and $20,000, respectively, which is included in interest expense in the accompanying consolidated statements of income. Foreign Currency Forward Contracts. On November 30, 2011, we forecasted a net exposure for December 31, 2011 (representing the difference between Euro and GBP-denominated receivables and Euro-denominated payables) of approximately 12,000 Euros and 328,000 GBPs. In order to partially offset such risks at November 30, 2011, we entered into a 30-day forward contract for the Euro and GBP with a notional amount of approximately 12,000 Euros and notional amount of 328,000 GBPs. On November 30, 2010, we forecasted a net exposure for December 31, 2010 (representing the difference between Euro and GBP-denominated receivables and Euro-denominated payables) of approximately 658,000 Euros and 222,000 GBPs. In order to partially offset such risks at November 30, 2010, we entered into a 30-day forward contract for the Euro and GBP with a notional amount of approximately 658,000 Euros and notional amount of 222,000 GBPs. We enter into similar transactions at various times during the year to partially offset exchange rate risks we bear throughout the year. These contracts are marked to market at each month-end. During the years ended December 31, 2011, 2010 and 2009, we recorded a net gain on all forward contracts of approximately $221,000, $126,000 and $83,000, respectively, which is included in other income in the accompanying consolidated statements of income. The fair value of our open positions at December 31, 2011 and 2010 was not material.

- Definition

The entire disclosure for the entity's entire derivative instruments and hedging activities. Describes an entity's risk management strategies, derivatives in hedging activities and non-hedging derivative instruments, the assets, obligations, liabilities, revenues and expenses arising therefrom, and the amounts of and methodologies and assumptions used in determining the amounts of such items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4H

-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5624258-113959

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4K

-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5708775-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6935481&loc=d3e41641-113959

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(n))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4E

-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5624181-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6935481&loc=d3e41635-113959

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4D

-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5624177-113959

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 30

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6441202&loc=d3e80720-113993

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6887037&loc=d3e80748-113994

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6935481&loc=d3e41620-113959

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4A

-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5618551-113959

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4J

-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5708773-113959

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 25

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6886632&loc=d3e76258-113986

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 133

-Paragraph 45

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 133

-Paragraph 44

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6887037&loc=d3e80784-113994

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5579245-113959

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4B

-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5624163-113959

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4C

-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5624171-113959

Reference 20: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6935481&loc=d3e41638-113959

Reference 21: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 1B

-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5580258-113959

Reference 22: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5579240-113959

+ Details

Commitments and Contingencies

12 Months Ended

Dec. 31, 2011

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

MITMENTS AND CONTINGENCIES

We are obligated under non-terminable operating leases for manufacturing facilities, finished good distribution, office space and equipment. Total rental expense on these operating leases and on our manufacturing and office building for the years ended December 31, 2011, 2010 and 2009, approximated $4.1 million, $3.7 million and $2.8 million, respectively.

The future minimum lease payments for operating leases as of December 31, 2011, consisted of the following (in thousands):



Years Ending	Operating
December 31	Leases

2012	$	3,444
2013	2,861
2014	2,353
2015	2,177
2016	2,165
Thereafter	6,378

Total minimum lease payments	$	19,378

Irish Government Development Agency Grants. As of December 31, 2011, we had entered into several grant agreements with the Irish Government Development Agency. We have recorded the grants related to research and development projects and costs of hiring and training employees as a reduction of operating expenses for the years ended December 31, 2011, 2010 and 2009 in the amounts of approximately $261,000, $40,000 and $177,000, respectively. Grants related to the acquisition of property and equipment purchased in Ireland are amortized as a reduction to depreciation expense over lives corresponding to the depreciable lives of such property and equipment. The balance of deferred credits related to such grants as of December 31, 2011 and 2010, was approximately $2.0 million and $1.8 million, respectively. During the years ended December 31, 2011, 2010 and 2009, approximately $106,000, $111,000 and $120,000, respectively, of the deferred credit was amortized as a reduction of operating expenses.

We have committed to repay the Irish government for grants received if we were to cease production in Ireland prior to the expiration of the grant liability period. The grant liability period is usually between five and eight years from the last claim made on a grant. As of December 31, 2011, the total amount of grants that could be subject to refund was approximately $500,000. Our management does not believe we will ever have to repay any of these grant monies, as we have no intention of ceasing operations in Ireland.

Letter of Credit. As of December 31, 2011, we had a standby letter of credit with Wells Fargo in the amount of approximately $88,000 which is related to the construction of our new building in South Jordan, Utah.

Litigation. In the ordinary course of business, and other than as described herein, we are involved in litigation and claims which management believes will not have a material effect on our financial position or results of operations.

Intellectual property rights, particularly patents, play a significant role in product development and help differentiate competitors in the medical device market. Competing companies file infringement lawsuits in attempts to bolster their intellectual property portfolios or enhance their financial standing. Intellectual property litigation is time consuming, costly and unpredictable. Monetary judgments, remedies or restitution are often not determined until the conclusion of trial court proceedings, which can be modified on appeal. Accordingly, the outcomes of pending litigation are difficult to predict or quantify. A third party has asserted that certain of our product offerings infringe their patents. We believe we have well-recognized defenses and intend to vigorously defend our position. While the pending litigation is in its preliminary stages and it is not possible to assess damages or predict an outcome, an adverse outcome could limit our ability to sell certain products or reduce our operating margin on the sale of these products and could have a material effect on our financial position, results of operations or liquidity. We are self-insured with respect to intellectual property infringement.

FDA Warning Letter. On February 1, 2012, Merit Medical Ireland Ltd., one of our wholly-owned subsidiaries (“Merit Ireland”), received a warning letter from the FDA (the “Warning Letter”) alleging that certain modifications to our hydrophilic coating process for our Laureate® Hydrophilic Guidewire (the “Guidewire”) constitute a significant change that could affect the Guidewire safety or effectiveness. In the Warning Letter, the FDA claimed that we do not have an approved application for premarket approval in effect pursuant to Section 515(a) of the FDCA or an approved application for an investigational device exemption under Section 520(g) of the Act. The FDA also claims in the Warning Letter that we did not properly notify the FDA of our intent to introduce the modified Guidewire into commercial distribution, as required by Section 510(k) of the Act.

We have submitted a formal response to the FDA and have ceased all Guidewire shipments into, within and from the United States. Such shipments represent less than one percent of our worldwide revenues for the year ended December 31, 2011. There can be no assurance that the FDA will accept our response and approve the actions we have taken with respect to the Guidewire or permit us to manufacture, sell, market or distribute the Guidewire as currently offered and packaged. Even though we have timely responded to the FDA, there can be no assurances regarding the length of time or cost it will take us to resolve these issues to our satisfaction and to the satisfaction of the FDA.

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Interpretation (FIN)

-Number 14

-Paragraph 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 9, 10, 11, 12

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

+ Details

Earnings Per Common Share (EPS)

12 Months Ended

Dec. 31, 2011

Earnings Per Share, Basic and Diluted [Abstract]

Earnings Per Common Share (EPS)

EARNINGS PER COMMON SHARE (EPS)

The computation of weighted average shares outstanding and the basic and diluted earnings per common share for the following periods consisted of the following (in thousands, except per share amounts):



	Net Income		Shares	Per Share Amount

Year ended December 31, 2011:
Basic EPS	$	23,044	39,086	$	0.59
Effect of dilutive stock options and warrants			647

Diluted EPS	$	23,044	39,733	$	0.58

Year ended December 31, 2010:
Basic EPS	$	12,460	35,290	$	0.35
Effect of dilutive stock options and warrants			686

Diluted EPS	$	12,460	35,976	$	0.35

Year ended December 31, 2009:
Basic EPS	$	22,530	35,014	$	0.64
Effect of dilutive stock options and warrants			744

Diluted EPS	$	22,530	35,758	$	0.63

For the years ended December 31, 2011, 2010 and 2009, approximately 909,000, 878,000 and 681,000, respectively, of stock options were not included in the computation of diluted earnings per share because their effect would have been anti-dilutive.

- Definition

The entire disclosure for earnings per share.

+ References+ Details

Employee Stock Purchase Plan Stock Options and Warrants

12 Months Ended

Dec. 31, 2011

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Employee Stock Purchase Plan Stock Options and Warrants

EMPLOYEE STOCK PURCHASE PLAN STOCK OPTIONS AND WARRANTS.

Our stock-based compensation primarily consists of the following plans:

2006 Long-Term Incentive Plan. In May 2006, our Board of Directors adopted and our shareholders approved, the Merit Medical Systems, Inc. 2006 Long-Term Incentive Plan (the “2006 Incentive Plan”). The 2006 Incentive Plan provides for the granting of stock options, stock appreciation rights, restricted stock, stock units (including restricted stock units) and performance awards. Options may be granted to directors, officers, outside consultants and key employees and may be granted upon such terms and such conditions as the Compensation Committee of our Board of Directors determines. Options will typically vest on an annual basis over a three to five year life (or one year if performance based) with contractual lives of seven to ten years. As of December 31, 2011, a total of approximately 1.4 million shares remained available to be issued under the 2006 Incentive Plan.

Employee Stock Purchase Plan. We have a qualified and a non-qualified Employee Stock Purchase Plan (“ESPP”), which has an expiration date of June 30, 2016. As of December 31, 2011, the total number of shares of Common Stock that remained available to be issued under our qualified plan was approximately 281,000 shares and 79,000 shares for our non-qualified plan. ESPP participants purchase shares on a quarterly basis at a price equal to 95% of the market price of the Common Stock at the end of the applicable offering period.

Stock-Based Compensation Expense. The stock-based compensation expense before income tax expense for the years ended December 31, 2011, 2010 and 2009, consisted of the following (in thousands):



	2011		2010		2009
Cost of goods sold	$	241	$	201	$	205
Research and development	86		56		57
Selling, general, and administrative	1,317		1,037		920
Stock-based compensation expense before taxes	$	1,644	$	1,294	$	1,182

We recognize stock-based compensation expense (net of a forfeiture rate) for those awards which are expected to vest on a straight-line basis over the requisite service period. We estimate the forfeiture rate based on our historical experience and expectations about future forfeitures. As of December 31, 2011, the total remaining unrecognized compensation cost related to non-vested stock options, net of expected forfeitures, was approximately $5.9 million and is expected to be recognized over a weighted average period of 3.6 years.

In applying the Black-Scholes methodology to the option grants, the fair value of our stock-based awards granted were estimated using the following assumptions for the periods indicated below:



	2011			2010	2009

Risk-free interest rate	0.68%	-	1.34%	2.24%	2.7%
Expected option life	4.2	-	6.0 years	6.0 years	6.0 years
Expected dividend yield	—%			—%	—%
Expected price volatility	42.11%	-	45.29%	41.4%	42.4%

The average risk-free interest rate is determined using the U.S. Treasury rate in effect as of the date of grant, based on the expected term of the stock option. We determine the expected term of the stock options using the historical exercise behavior of employees. The expected price volatility was determined using a weighted average of daily historical volatility of our stock price over the corresponding expected option life and implied volatility based on recent trends of the daily historical volatility. For options with a vesting period, compensation expense is recognized on a straight-line basis over the service period, which corresponds to the vesting period. Compensation expense is recognized immediately for options that are fully vested on the date of grant. During the years ended December 31, 2011, 2010 and 2009, 844,000, 125,000 and 175,000 stock-based compensation grants were made, respectively, for a total fair value of approximately $4.3 million, $705,000 and $1.0 million, net of estimated forfeitures, respectively.

The table below presents information related to stock option activity for the years ended December 31, 2011, 2010 and 2009 (in thousands):



	2011		2010		2009
Total intrinsic value of stock options exercised	$	9,433	$	1,928	$	2,757
Cash received from stock option exercises	7,197		1,330		1,690
Net income tax benefit from the exercises of stock options	3,122		399		987

Changes in stock options for the year ended December 31, 2011, consisted of the following (shares and intrinsic value in thousands):



	Number of Shares		Weighted Average Exercise Price		Remaining Contractual Term (in years)	Intrinsic Value
2011:
Beginning balance	4,389		$	10.56
Granted	844		13.75
Exercised	(1,099	)	7.69
Forfeited/expired	(57	)	13.00
Outstanding at December 31	4,077		11.96		3.5	$	7,877
Exercisable	2,744		11.43		2.5	7,090
Ending vested and expected to vest	4,049		11.95		3.5	7,871

The weighted average grant-date fair value of options granted during the years ended December 31, 2011, 2010 and 2009 was $5.28, $5.64 and $5.49, respectively.

The following table summarizes information about stock options outstanding at December 31, 2011 (shares in thousands):



			Options Outstanding				Options Exercisable
Range of Exercise			Number Outstanding	Weighted Average Remaining Contractual Life (in years)	Weighted Average Exercise Price		Number Exercisable	Weighted Average Exercise Price
$7.65	-	$9.70	1,021	1.6	$	8.74	926	$	8.64
$9.71	-	$11.53	1,111	3.3	10.99		885	10.85
$12.02	-	$13.75	1,286	5.5	13.25		364	12.10
$13.82	-	$17.34	659	2.8	16.09		569	16.45
$7.65	-	$17.34	4,077				2,744

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 64, 65, A240

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Statement of Position (SOP)

-Number 93-6

-Paragraph 53

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 40

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

+ Details

Segment Reporting And Foreign Operations

12 Months Ended

Dec. 31, 2011

Segment Reporting [Abstract]

Segment Reporting And Foreign Operations

SEGMENT REPORTING AND FOREIGN OPERATIONS

We report our operations in two operating segments: cardiovascular and endoscopy. Our cardiovascular segment consists of cardiology and radiology medical device products which assist in diagnosing and treating coronary artery disease, peripheral vascular disease and other non-vascular diseases and includes the embolization devices we acquired through BioSphere. Our endoscopy segment consists of gastroenterology and pulmonology medical device products which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures caused by malignant tumors. We evaluate the performance of our operating segments based on operating income (loss). Listed below are the sales by business segment for the years ended December 31, 2011, 2010 and 2009 (in thousands):



	Year Ended December 31,
	% Change		2011		% Change		2010		% Change		2009
Cardiovascular
Stand-alone devices	15	%	$	101,959	16	%	$	88,586	12	%	$	76,075
Custom kits and procedure trays	11	%	91,532		11	%	82,799		12	%	74,541
Inflation devices	8	%	67,353		2	%	62,495		(1	)%	61,058
Catheters	23	%	55,357		18	%	44,824		23	%	38,126
Embolization devices	247	%	31,229		—		9,003		—		—
Total	21	%	347,430		15	%	287,707		10	%	249,800

Endoscopy
Endoscopy devices	33	%	12,019		18	%	9,048		—		7,662

Total	21	%	$	359,449	15	%	$	296,755	13	%	$	257,462

During the years ended December 31, 2011, 2010 and 2009, we had foreign sales of approximately $125.9 million, $95.2 million and $86.4 million, respectively, or approximately 35%, 32% and 34%, respectively, of total sales, primarily in China, Japan, Germany, France and the United Kingdom. Foreign sales are attributed based on location of the customer receiving the product.

Our long-lived assets by geographic area at December 31, 2011, 2010 and 2009, consisted of the following (in thousands):



	2011		2010		2009
United States	$	134,393	$	97,881	$	89,428
Ireland	36,008		22,203		17,148
Other foreign countries	8,739		7,971		8,070

Total	$	179,140	$	128,055	$	114,646

Financial information relating to our reportable operating segments and reconciliations to the consolidated totals for the years ended December 31, 2011, 2010 and 2009, are as follows (in thousands):



	2011			2010			2009
Revenues
Cardiovascular	$	347,430		$	287,707		$	249,800
Endoscopy	12,019			9,048			7,662
Total revenues	359,449			296,755			257,462

Operating expenses
Cardiovascular	122,600			93,884			69,097
Endoscopy	9,678			9,066			6,858
Total operating expenses	132,278			102,950			75,955

Goodwill impairment charge
Cardiovascular	—			—			—
Endoscopy	—			8,344			—
Total goodwill impairment charge	—			8,344			—

Operating income (loss)
Cardiovascular	38,010			30,176			35,836
Endoscopy	(4,820		)	(12,972		)	(2,989		)
Total operating income	33,190			17,204			32,847

Total other income (expense) - net	(315		)	(416		)	247
Income tax expense	9,831			4,328			10,564

Net income	$	23,044		$	12,460		$	22,530

Total assets by business segment at December 31, 2011, 2010 and 2009, consisted of the following (in thousands):



	2011		2010		2009
Cardiovascular	$	434,747	$	355,718	$	249,726
Endoscopy	12,270		13,762		21,787

Total	$	447,017	$	369,480	$	271,513

Total depreciation and amortization by business segment for the years ended December 31, 2011, 2010 and 2009, consisted of the following (in thousands):



	2011		2010		2009

Cardiovascular	$	18,219	$	13,851	$	11,406
Endoscopy	975		1,005		865
Total	$	19,194	$	14,856	$	12,271

Total capital expenditures by business segment for the years ended December 31, 2011, 2010 and 2009, consisted of the following (in thousands):



	2011		2010		2009

Cardiovascular	$	58,775	$	23,494	$	18,475
Endoscopy	420		154		3
Total	$	59,195	$	23,648	$	18,478

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 32

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 33

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 131

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 34

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 35

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 42

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 40

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 31

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 41

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 29

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599

+ Details

Royalty Agreements	12 Months Ended
Royalty Agreements	Dec. 31, 2011
Royalty Agreements [Abstract]
Royalty Agreements	ROYALTY AGREEMENTS During 2007, in connection with the purchase of the ProGuide™ chronic dialysis catheter from Datascope Corporation, a New Jersey corporation, ("Datascope") we entered into a running royalty agreement as partial consideration of the assignment of acquired intellectual property to us. Under this agreement, we agreed to pay Datascope a royalty of 5% of net sales, with annual minimum royalty payments of $50,000 for calendar years 2009 through 2013. During each of the years ended December 31, 2011, 2010 and 2009, we paid or accrued a royalty of $50,000 under this agreement. During 2010, in connection with our acquisition of BioSphere, we entered into a running royalty agreement as part of a partnership between BioSphere and L’Assistance Publique-Hôpitaux de Paris, referred to as “AP-HP,” pursuant to which AP-HP has granted us the exclusive license to use two United States patents and their foreign counterparts that we jointly own with AP-HP relating to microspheres. We are required to pay to AP-HP a royalty on the commercial sale of any products that incorporate technology covered by the patents. We may sublicense these exclusive rights under the agreement only with the prior written consent of AP-HP, which consent cannot be unreasonably withheld. Under the terms of the royalty agreement our exclusive license extends for the duration of both (i) the jointly owned U.S. and foreign counterpart patents which will expire in 2014 and 2012, respectively, and (ii) the products and specialties implementing the patents. On January 26, 2010, BioSphere filed patent applications which, if issued, will extend the royalty payments until approximately January 2031. The royalty rate in the agreement is 5.0% of net sales until the patents expire, and 2.5% of net sales thereafter as long as the product is sold. We paid or accrued approximately $1.3 million and $401,000 in royalty payments to AP-HP for the years ended December 31, 2011 and 2010, respectively, after the BioSphere acquisition. See also Note 2 for a discussion of additional future royalty commitments related to acquisitions.

Employee Benefit Plans	12 Months Ended
Employee Benefit Plans	Dec. 31, 2011
Defined Contribution Pension and Other Postretirement Plans Disclosure [Abstract]
Employee Benefit Plans	EMPLOYEE BENEFIT PLANS We have a contributory 401(k) savings and profit sharing plan (the “Plan”) covering all U.S. full-time employees who are at least 18 years of age. The Plan has a 90 day minimum service requirement. We may contribute, at our discretion, matching contributions based on the employees’ compensation. Contributions we made to the Plan for the years ended December 31, 2011, 2010 and 2009, totaled approximately $1.2 million, $1.2 million and $883,000, respectively. We have defined contribution plans covering some of our foreign employees. We contribute between three and 36% of the employee’s compensation for certain foreign non-management employees, and between ten and 36% of the employee’s compensation for certain foreign management employees. Contributions made to these plans for the years ended December 31, 2011, 2010 and 2009, totaled approximately $469,000, $565,000 and $550,000, respectively.

Quarterly Results of Operations (Unaudited)

12 Months Ended

Dec. 31, 2011

Quarterly Financial Information Disclosure [Abstract]

Quarterly Results of Operations (Unaudited)

QUARTERLY RESULTS OF OPERATIONS (UNAUDITED)

Quarterly data for the years ended December 31, 2011 and 2010, consisted of the following (in thousands, except per share amounts):



	Quarter Ended
	March 31		June 30		September 30			December 31

2011

Net sales	$	86,631	$	91,249	$	90,477		$	91,092
Gross profit	39,785		42,484		41,054			42,145
Income from operations	10,210		10,847		6,507			5,626
Income tax expense	3,159		3,746		2,120			806
Net income	6,639		6,872		4,563			4,970
Basic earnings per common share	0.19		0.19		0.11			0.12
Diluted earnings per common share	0.18		0.18		0.11			0.12

2010

Net sales	$	67,432	$	74,948	$	73,172		$	81,203
Gross profit	28,435		32,458		31,247			36,358
Income (loss) from operations	6,346		8,777		(3,442		)	5,523
Income tax expense (benefit)	1,822		3,124		(1,539		)	921
Net income (loss)	4,508		5,715		(1,973		)	4,210
Basic earnings (loss) per common share	0.13		0.16		(0.06		)	0.12
Diluted earnings (loss) per common share	0.13		0.16		(0.06		)	0.12

Basic and diluted earnings (loss) per share are computed independently for each of the quarters presented. Therefore, the sum of the quarterly amounts may not equal the total computed for the year.

- Definition

The entire disclosure for the quarterly financial data in the annual financial statements. The disclosure may include a tabular presentation of financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income or loss before extraordinary items and earnings per share data. It also includes an indication if the information in the note is unaudited, comments on the aggregate effect of year-end adjustments, and an explanation of matters or transactions that affect comparability or are pertinent to an understanding of the information furnished.

+ References+ Details

Fair Value Measurements

12 Months Ended

Dec. 31, 2011

Fair Value Disclosures [Abstract]

Fair Value Measurements

FAIR VALUE MEASUREMENTS

Our financial assets and liabilities carried at fair value measured on a recurring basis as of December 31, 2011 and 2010, consisted of the following (in thousands):

Fair Value Measurements Using

Total Fair

Quoted prices in

Significant other

Significant

Value at

active markets

observable inputs

Unobservable inputs

Description

December 31, 2011

(Level 1)

(Level 2)

(Level 3)

Marketable securities (1)

2,798

—

Fair Value Measurements Using

Total Fair

Quoted prices in

Significant other

Significant

Value at

active markets

observable inputs

Unobservable inputs

Description

December 31, 2010

(Level 1)

(Level 2)

(Level 3)

Interest rate swap (2)

1,159

—

1,159

—

(1) Our marketable securities, which consist entirely of available-for-sale equity securities, are valued using market prices in active markets. Level 1 instrument valuations are obtained from real-time quotes for transactions in active exchange markets involving identical assets.

(2) The fair value of the interest rate swap is determined based on forward yield curves.

During the years ended December 31, 2011, 2010 and 2009, we had losses of approximately $103,000, $8.5 million, $154,000, respectively, related to the measurement of non-financial assets at fair value on a nonrecurring basis subsequent to their initial recognition. Of the total loss in 2010, approximately $8.3 million was related to the impairment of our goodwill related to our endoscopy reporting unit (see Note 4). The fair value of these non-financial assets was measured using Level 3 inputs. As of December 31, 2010, there was no goodwill remaining in our consolidated financial statements related to the endoscopy reporting unit.

The carrying amount of cash and cash equivalents, receivables, and trade payables approximates fair value because of the immediate, short-term maturity of these financial instruments. The carrying amount of long-term debt approximates fair value, as determined by borrowing rates estimated to be available to us for debt with similar terms and conditions.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13504-108611

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6925170&loc=d3e19296-110258

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13433-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 133

-Paragraph 44A, 44B

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 15C, 15D

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 15A

-Subparagraph a-d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 15B

-Subparagraph a, b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 3, 10, 14, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 157

-Paragraph 32, 33, 34

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 159

-Paragraph 17-22, 27, 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6925170&loc=d3e19207-110258

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13537-108611

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

+ Details

Stockholders' Equity	12 Months Ended
Stockholders' Equity	Dec. 31, 2011
Stockholders' Equity Note [Abstract]
Stockholders' Equity	STOCKHOLDERS' EQUITY Issuance of Common Stock. On June 22, 2011, we completed an equity public offering of 5,520,000 shares of Common Stock and received proceeds of approximately $87.7 million, which is net of approximately $4.6 million in underwriting discounts and commissions and approximately $127,000 in other direct costs incurred and paid by us in connection with this equity offering. Stock Split. On April 21, 2011, our Board of Directors authorized a 5-for-4 forward stock split of our Common Stock, which was effected in the form of a stock dividend of one share of Common Stock for every four shares of Common Stock outstanding on the record date. On May 5, 2011, we completed the forward stock split through a stock dividend to shareholders of record as of May 2, 2011. Our Board of Directors also made corresponding adjustments to the number of shares subject to, and the exercise price of, outstanding options and other rights to acquire shares of our Common Stock. All earnings per common share and common share data set forth in the foregoing consolidated financial statements (and notes thereto) have been adjusted to reflect the split. Repurchase of Our Common Stock. On April 30, 2007, our Board of Directors approved the repurchase of up to 1.4 million shares of Common Stock. During the first quarter of 2009, we repurchased a total of 250,158 shares of Common Stock for approximately $2.5 million. We did not repurchase any shares of Common Stock during 2011 and 2010.

- Definition

The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable). Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187143-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 4

-Section 08

-Paragraph d

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Chapter 1

-Section B

-Paragraph 7, 11A

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 20: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Article 4

Reference 21: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 22: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 23: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

+ Details

Subsequent Event	12 Months Ended
Subsequent Event	Dec. 31, 2011
Subsequent Events [Abstract]
Subsequent Event	SUBSEQUENT EVENT On January 31, 2012, we consummated the transactions contemplated by an Asset Purchase Agreement we executed with Ostial Solutions, LLC, a privately-held company based in Kalamazoo, Michigan ("Ostial Solutions"), and acquired substantially all of the assets of Ostial Solutions under terms which required $10.0 million of the purchase price to be paid at closing, $6.5 million of the purchase price to be paid within six months of closing and additional payments of up to $13.5 million based on our future product sales. The primary asset of Ostial Solutions is the patented Ostial Pro® Stent Positioning System, which facilitates precise stent implantation in coronary and renal aorto-ostial lesions, eliminating guesswork when deploying a stent at the "true" ostium of the vessel. The initial accounting for this acquisition has not yet been completed.

Finacial Statement Schedule

12 Months Ended

Dec. 31, 2011

Valuation and Qualifying Accounts Disclosure [Line Items]

Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]

(2) Financial Statement Schedule.

— Schedule II - Valuation and qualifying accounts

Years Ended December 31, 2011, 2010 and 2009

(In thousands)



Description	Balance at Beginning of Year			Additions Charged to Costs and Expenses (a)			Deduction (b)		Balance at End of Year

ALLOWANCE FOR UNCOLLECTIBLE ACCOUNTS:

2009	$	(505	)	$	(214	)	$	178	$	(541	)
2010	(541		)	(193		)	141		(593		)
2011	(593		)	(12		)	141		(464		)

(a) We record a bad debt provision based upon historical experience and a review of individual customer balances.

(b) When an individual customer balance becomes impaired and is deemed uncollectible a deduction is made against the allowance for uncollectible accounts.

Years Ended December 31, 2011, 2010 and 2009

(In thousands)



Description	Balance at Beginning of Year	Additions Charged to Costs and Expenses (c)		Deduction	Balance at End of Year

TAX VALUATION ALLOWANCE:

2009	—	—		—	—
2010	—	—		—	—
2011	—	(361	)	—	(361	)

(c) We record a valuation allowance against a deferred tax asset when it is determined that it is more likely than not that the deferred tax asset will not be realized.

Organization And Summary Of Significant Accounting Policies Acounting Policies (Policies)

12 Months Ended

Dec. 31, 2011

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Use of Estimates, Policy [Policy Text Block]

Consolidation, Policy [Policy Text Block]

Principles of Consolidation. The consolidated financial statements include our wholly-owned subsidiaries. Intercompany balances and transactions have been eliminated.

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash and Cash Equivalents. For purposes of the statements of cash flows, we consider interest bearing deposits with an original maturity date of three months or less to be cash equivalents.

Receivables, Policy [Policy Text Block]

Inventory, Policy [Policy Text Block]

Goodwill and Intangible Assets, Policy [Policy Text Block]



Customer lists	5	-	15 years
Developed technology	5	-	15 years
Distribution agreements	5	-	11 years
License agreements and trademarks	5	-	15 years
Covenant not to compete	3	-	10 years
Patents	17 years
Royalty agreements	5 years

Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]

Property, Plant and Equipment, Policy [Policy Text Block]



Buildings	40 years
Manufacturing equipment	4	-	20 years
Furniture and fixtures	3	-	10 years
Land improvements	10	-	20 years
Leasehold improvements	4	-	25 years

Depreciation expense related to property and equipment for the years ended December 31, 2011, 2010 and 2009 was approximately $13.2 million, $11.4 million, and $10.0 million, respectively.

Deferred compensation policy text block [Policy Text Block]

Investment, Policy [Policy Text Block]

Other assets policy text block [Policy Text Block]

Deferred credits [Policy Text Block]

Revenue Recognition, Policy [Policy Text Block]

Shipping and Handling Cost, Policy [Policy Text Block]

Cost of Sales, Policy [Policy Text Block]

Research and Development Expense, Policy [Policy Text Block]

Research and Development. Research and development costs are expensed as incurred.

Income Tax, Policy [Policy Text Block]

Earnings Per Share, Policy [Policy Text Block]

Fair Value of Financial Instruments, Policy [Policy Text Block]

Level 1: Quoted market prices in active markets for identical assets or liabilities.

Level 2: Observable market-based inputs or inputs that are corroborated by market data.

Level 3: Unobservable inputs that are not corroborated by market data.

Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]

Concentration of Credit Risk [Policy Text Block]

Foreign Currency Transactions and Translations Policy [Policy Text Block]

Derivatives, Policy [Policy Text Block]

Accumulated Other Comprehensive Income (Loss) [Policy Text Block]

Organization And Summary Of Significant Accounting Policies Goodwill And Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2011

Accounting Policies [Abstract]

Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]

Intangible assets are amortized on a straight-line basis, except for customer lists, which are generally amortized on an accelerated basis, over the following useful lives:



Customer lists	5	-	15 years
Developed technology	5	-	15 years
Distribution agreements	5	-	11 years
License agreements and trademarks	5	-	15 years
Covenant not to compete	3	-	10 years
Patents	17 years
Royalty agreements	5 years

Organization And Summary Of Significant Accounting Policies Property Plant And Equipment (Tables)

12 Months Ended

Dec. 31, 2011

Property, Plant and Equipment [Line Items]

Property, Plant and Equipment [Table Text Block]

Depreciation is computed using the straight-line method over estimated useful lives as follows:



Buildings	40 years
Manufacturing equipment	4	-	20 years
Furniture and fixtures	3	-	10 years
Land improvements	10	-	20 years
Leasehold improvements	4	-	25 years

- Definition

Tabular disclosure of the useful life and salvage value of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.

+ References+ Details

Acquisitions Acquisitions (Tables)

12 Months Ended

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2009

Business Acquisition [Line Items]

Business Acquisition, Pro Forma Information [Table Text Block]



	Year Ended December 31, 2010				Year Ended December 31, 2009
	As Reported		Pro Forma		As Reported		Pro Forma
Sales	$	296,755	$	317,382	$	257,462	$	288,589
Net income	12,460		7,258		22,530		17,000
Earnings per common share:
Basic	$	0.35	$	0.21	$	0.64	$	0.49
Diluted	$	0.35	$	0.20	$	0.63	$	0.48



	Year Ended December 31, 2009
	As Reported		Pro Forma
Sales	$	257,462	$	259,914
Net income	22,530		22,470
Earnings per common share:
Basic	$	0.64	$	0.64
Diluted	$	0.63	$	0.63

ScheduleOfBusinessAcquisitionsByAcquisitionBiosearch [Table Text Block]

The purchase price was allocated as follows (in thousands):



Assets Acquired
Inventories	$	188
Property and equipment	31
Intangibles
Developed technology	380
Customer lists	660
Non-compete	25
Goodwill	316
Total assets acquired	1,600

Liabilities Assumed	—

Net assets acquired	$	1,600

ScheduleOfBusinessAcquisitionsByAcquisitionAlveolus [Table Text Block]

The purchase price was allocated as follows (in thousands):



Assets Acquired
Inventories	$	1,741
Trade receivables	974
Other assets	241
Property and equipment	547
Intangibles
Developed technology	5,700
Trademarks	1,400
Customer lists	1,100
In-process research and development	400
Goodwill	8,028
Total assets acquired	20,131

Liabilities Assumed
Accounts payable	467
Other liabilities	572
Total liabilities assumed	1,039

Net assets acquired	$	19,092

ScheduleOfBusinessAcquisitionsByAcquisitionHatch [Table Text Block]

The purchase price was allocated as follows (in thousands):



Assets Acquired
Intangibles
Developed technology	$	8,100
Customer list	590
Non-compete	240
Trademark	650
Goodwill	11,420
Total assets acquired	21,000

Liabilities Assumed	—

Net assets acquired	$	21,000

ScheduleOfBusinessAcquisitionsByAcquisitionBiosphere [Table Text Block]

As of December 31, 2010, the BioSphere purchase price was allocated as follows (in thousands):



Assets Acquired
Marketable securities	$	9,673
Trade receivables	4,529
Inventories	5,694
Other assets	1,340
Property and equipment	546
Deferred income tax assets	16,012
Intangibles
Developed technology	19,000
Customer list	7,900
License agreement	380
Trademark	3,200
Goodwill	34,016
Total assets acquired	102,290

Liabilities Assumed
Accounts payable	322
Accrued expenses	3,617
Deferred income tax liabilities	729
Liabilities related to unrecognized tax benefits	961
Other liabilities	936
Total liabilities assumed	6,565

Net assets acquired, net of cash acquired of $274	$	95,725

Schedule of Business Acquisitions, by Acquisition [Table Text Block]

The purchase price was preliminarily allocated as follows (in thousands):



Assets Acquired
Property and equipment	$	73
Intangibles
Developed technology	3,200
Customer lists	300
Goodwill	2,697
Total assets acquired	6,270

Liabilities Assumed
Contingent liabilities	1,270

Net assets acquired	$	5,000

- Definition

Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.

+ References+ Details

- Definition

Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141

-Paragraph 51

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141

-Paragraph 52

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141R

-Paragraph 68

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141R

-Appendix F

-Paragraph F4

-Subparagraph e

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6909870&loc=d3e1392-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6909870&loc=d3e1486-128463

+ Details

Goodwill and Intangible Assets Goodwill and Intangible Assets (tables)

12 Months Ended

Dec. 31, 2011

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Goodwill [Table Text Block]

The changes in the carrying amount of goodwill for the years ended December 31, 2011 and 2010, are as follows (in thousands):



	2011			2010
Goodwill balance at January 1	$	58,675		$	33,002
Impairment charge	—			(8,343		)
Adjustment related to previous acquisitions	(228		)	—
Additions as the result of acquisitions	2,697			34,016
Goodwill balance at December 31	$	61,144		$	58,675

Schedule of Finite-Lived Intangible Assets by Major Class [Table Text Block]

Other intangible assets at December 31, 2011 and 2010, consisted of the following (in thousands):



	2011
	Gross					Net
	Carrying Amount		Accumulated Amortization			Carrying Amount
Patents	$	6,455	$	(1,704	)	$	4,751
Distribution agreement	2,426		(900		)	1,526
License agreements	1,983		(436		)	1,547
Trademark	5,746		(1,014		)	4,732
Covenant not to compete	315		(108		)	207
Customer lists	14,277		(5,786		)	8,491
Royalty agreements	267		(267		)	—

Total	$	31,469	$	(10,215	)	$	21,254



	2010
	Gross					Net
	Carrying Amount		Accumulated Amortization			Carrying Amount
Patents	$	4,631	$	(1,445	)	$	3,186
Distribution agreement	2,426		(641		)	1,785
License agreements	1,833		(352		)	1,481
Trademark	5,761		(636		)	5,125
In-process research and development	400		—			400
Covenant not to compete	315		(67		)	248
Customer lists	13,973		(3,287		)	10,686
Royalty agreements	267		(267		)	—

Total	$	29,606	$	(6,695	)	$	22,911

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

Estimated amortization expense for the intangible assets for the next five years consists of the following as of December 31, 2011 (in thousands):



Year Ending December 31
2012	$	5,767
2013	5,550
2014	5,090
2015	4,818
2016	4,811

- Definition

Tabular disclosure of amortizable intangibles assets, in total and by major class, including the gross carrying amount and accumulated amortization. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.

+ References+ Details

- Definition

Tabular disclosure of goodwill by reportable segment and in total. Disclosure details may include, but are not limited to, the carrying amount of goodwill, goodwill acquired during the year, goodwill impairment losses recognized, goodwill written-off due to the sale of a business unit, goodwill not yet allocated, and any other changes to goodwill.

+ References+ Details

Income Taxes Income Tax Disclosure (Tables)

12 Months Ended

Dec. 31, 2011

Income Tax Disclosure [Abstract]

Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]

For the years ended December 31, 2011, 2010 and 2009, income before income taxes is broken out between U.S. and foreign-sourced operations and consisted of the following (in thousands):



	2011		2010		2009
Domestic	$	21,123	$	10,551	$	26,918
Foreign	11,752		6,237		6,176

Total	$	32,875	$	16,788	$	33,094

Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]

The components of the provision for income taxes for the years ended December 31, 2011, 2010 and 2009 consisted of the following (in thousands):



	2011		2010			2009

Current expense:
Federal	$	5,662	$	3,547		$	7,846
State	1,001		595			689
Foreign	1,491		740			238

Total current expense	8,154		4,882			8,773

Deferred expense (benefit):
Federal	1,121		30			1,264
State	74		(545		)	227
Foreign	482		(39		)	300

Total deferred expense (benefit)	1,677		(554		)	1,791

Total	$	9,831	$	4,328		$	10,564

Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]



	2011			2010			2009

Computed federal income tax expense at statutory rate of 35%	$	11,506		$	5,876		$	11,583
State income taxes	699			33			596
Tax credits	(778		)	(530		)	(670		)
Production activity deduction	(425		)	(355		)	(215		)
Foreign tax rate differential	(1,297		)	(1,212		)	(1,062		)
Uncertain tax positions	281			(372		)	114
Deferred compensation insurance assets	88			(133		)	(196		)
Transaction-related expenses	—			323			—
Other — including the effect of graduated rates	(243		)	698			414

Total income tax expense	$	9,831		$	4,328		$	10,564

Schedule of Deferred Tax Assets and Liabilities [Table Text Block]

Deferred income tax assets and liabilities at December 31, 2011 and 2010, consisted of the following temporary differences and carry-forward items (in thousands):



	2011			2010

Deferred income tax assets:
Allowance for uncollectible accounts receivable	$	188		$	242
Accrued compensation expense	3,064			3,230
Inventory differences	364			1,796
Net operating loss carry-forwards	22,689			26,273
Deferred revenue	273			214
Stock-based compensation expense	2,166			1,923
Uncertain tax positions	1,052			577
Other	1,848			1,686
Total deferred income tax assets	31,644			35,941

Deferred income tax liabilities:
Prepaid expenses	(823		)	(493		)
Property and equipment	(17,236		)	(18,103		)
Intangible assets	(6,169		)	(9,320		)
Other	(97		)	(505		)
Total deferred income tax liabilities	(24,325		)	(28,421		)
Valuation allowance	(361		)	—
Net deferred income tax assets	$	6,958		$	7,520

Reported as:
Deferred income tax assets - Current	$	3,704		$	4,647
Deferred income tax assets - Long-term	5,366			4,140
Deferred income tax liabilities - Current	—			—
Deferred income tax liabilities - Long-term	(2,112		)	(1,267		)

Net deferred income tax assets	$	6,958		$	7,520

Summary of Income Tax Contingencies [Table Text Block]



Tabular Roll-forward	2011			2010			2009

Unrecognized tax benefits, opening balance	$	2,952		$	2,790		$	2,668
Gross increases in tax positions taken in a prior year	347			518			163
Gross decreases in tax positions taken in a prior year	—			(51		)	(40		)
Gross increases in tax positions taken in the current year	865			520			710
Settlements with taxing authorities	(507		)	—			—
Lapse of applicable statute of limitations	(544		)	(825		)	(711		)
Unrecognized tax benefits, ending balance	$	3,113		$	2,952		$	2,790

- Definition

Tabular disclosure of tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities (i.e., uncertain tax positions) and other types of income tax contingencies, including: (1) the policy on classification of interest and penalties; (2) a tabular reconciliation of the total amounts of unrecognized tax benefits at the beginning and end of the period; the total amount(s) of: (3) unrecognized tax benefits that, if recognized, would affect the effective tax rate, and (4) interest and penalties recognized in each of the income statement and balance sheet; (5) for positions for which it is reasonably possible that the total amounts unrecognized will significantly change within 12 months of the reporting date the: (i) nature of the uncertainty, (ii) nature of the event that could occur that would cause the change, and (iii) an estimate of the range of the reasonably possible change or a statement that an estimate of the range cannot be made; and (6) a description of tax years that remain subject to examination by major tax jurisdictions.

+ References+ Details

Employee Stock Purchase Plan Stock Options and Warrants Employee Stock Purchase Plan Stock Options and Warrants (Tables)

12 Months Ended

Dec. 31, 2011

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]

The stock-based compensation expense before income tax expense for the years ended December 31, 2011, 2010 and 2009, consisted of the following (in thousands):



	2011		2010		2009
Cost of goods sold	$	241	$	201	$	205
Research and development	86		56		57
Selling, general, and administrative	1,317		1,037		920
Stock-based compensation expense before taxes	$	1,644	$	1,294	$	1,182

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

In applying the Black-Scholes methodology to the option grants, the fair value of our stock-based awards granted were estimated using the following assumptions for the periods indicated below:



	2011			2010	2009

Risk-free interest rate	0.68%	-	1.34%	2.24%	2.7%
Expected option life	4.2	-	6.0 years	6.0 years	6.0 years
Expected dividend yield	—%			—%	—%
Expected price volatility	42.11%	-	45.29%	41.4%	42.4%

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]

The table below presents information related to stock option activity for the years ended December 31, 2011, 2010 and 2009 (in thousands):



	2011		2010		2009
Total intrinsic value of stock options exercised	$	9,433	$	1,928	$	2,757
Cash received from stock option exercises	7,197		1,330		1,690
Net income tax benefit from the exercises of stock options	3,122		399		987

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

Changes in stock options for the year ended December 31, 2011, consisted of the following (shares and intrinsic value in thousands):



	Number of Shares		Weighted Average Exercise Price		Remaining Contractual Term (in years)	Intrinsic Value
2011:
Beginning balance	4,389		$	10.56
Granted	844		13.75
Exercised	(1,099	)	7.69
Forfeited/expired	(57	)	13.00
Outstanding at December 31	4,077		11.96		3.5	$	7,877
Exercisable	2,744		11.43		2.5	7,090
Ending vested and expected to vest	4,049		11.95		3.5	7,871

Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]

The following table summarizes information about stock options outstanding at December 31, 2011 (shares in thousands):



			Options Outstanding				Options Exercisable
Range of Exercise			Number Outstanding	Weighted Average Remaining Contractual Life (in years)	Weighted Average Exercise Price		Number Exercisable	Weighted Average Exercise Price
$7.65	-	$9.70	1,021	1.6	$	8.74	926	$	8.64
$9.71	-	$11.53	1,111	3.3	10.99		885	10.85
$12.02	-	$13.75	1,286	5.5	13.25		364	12.10
$13.82	-	$17.34	659	2.8	16.09		569	16.45
$7.65	-	$17.34	4,077				2,744

- Definition

Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.

+ References+ Details

- Definition

Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.

+ References+ Details

Segment Reporting And Foreign Operations Segment Reporting And Foreign Operations (Tables)

12 Months Ended

Dec. 31, 2011

Segment Reporting [Abstract]

Revenue from External Customers by Products and Services [Table Text Block]

Listed below are the sales by business segment for the years ended December 31, 2011, 2010 and 2009 (in thousands):



	Year Ended December 31,
	% Change		2011		% Change		2010		% Change		2009
Cardiovascular
Stand-alone devices	15	%	$	101,959	16	%	$	88,586	12	%	$	76,075
Custom kits and procedure trays	11	%	91,532		11	%	82,799		12	%	74,541
Inflation devices	8	%	67,353		2	%	62,495		(1	)%	61,058
Catheters	23	%	55,357		18	%	44,824		23	%	38,126
Embolization devices	247	%	31,229		—		9,003		—		—
Total	21	%	347,430		15	%	287,707		10	%	249,800

Endoscopy
Endoscopy devices	33	%	12,019		18	%	9,048		—		7,662

Total	21	%	$	359,449	15	%	$	296,755	13	%	$	257,462

Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]

Our long-lived assets by geographic area at December 31, 2011, 2010 and 2009, consisted of the following (in thousands):



	2011		2010		2009
United States	$	134,393	$	97,881	$	89,428
Ireland	36,008		22,203		17,148
Other foreign countries	8,739		7,971		8,070

Total	$	179,140	$	128,055	$	114,646

Schedule of Segment Reporting Information, by Segment [Table Text Block]

Financial information relating to our reportable operating segments and reconciliations to the consolidated totals for the years ended December 31, 2011, 2010 and 2009, are as follows (in thousands):



	2011			2010			2009
Revenues
Cardiovascular	$	347,430		$	287,707		$	249,800
Endoscopy	12,019			9,048			7,662
Total revenues	359,449			296,755			257,462

Operating expenses
Cardiovascular	122,600			93,884			69,097
Endoscopy	9,678			9,066			6,858
Total operating expenses	132,278			102,950			75,955

Goodwill impairment charge
Cardiovascular	—			—			—
Endoscopy	—			8,344			—
Total goodwill impairment charge	—			8,344			—

Operating income (loss)
Cardiovascular	38,010			30,176			35,836
Endoscopy	(4,820		)	(12,972		)	(2,989		)
Total operating income	33,190			17,204			32,847

Total other income (expense) - net	(315		)	(416		)	247
Income tax expense	9,831			4,328			10,564

Net income	$	23,044		$	12,460		$	22,530

Reconciliation of Assets from Segment to Consolidated [Table Text Block]

Total assets by business segment at December 31, 2011, 2010 and 2009, consisted of the following (in thousands):



	2011		2010		2009
Cardiovascular	$	434,747	$	355,718	$	249,726
Endoscopy	12,270		13,762		21,787

Total	$	447,017	$	369,480	$	271,513

Segment Depreciation And Amortization [Table Text Block]

Total depreciation and amortization by business segment for the years ended December 31, 2011, 2010 and 2009, consisted of the following (in thousands):



	2011		2010		2009

Cardiovascular	$	18,219	$	13,851	$	11,406
Endoscopy	975		1,005		865
Total	$	19,194	$	14,856	$	12,271

Segment Capital Expenditures [Table Text Block]

Total capital expenditures by business segment for the years ended December 31, 2011, 2010 and 2009, consisted of the following (in thousands):



	2011		2010		2009

Cardiovascular	$	58,775	$	23,494	$	18,475
Endoscopy	420		154		3
Total	$	59,195	$	23,648	$	18,478

- Definition

Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.

+ References+ Details

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References+ Details

Quarterly Results of Operations (Unaudited) Quarterly Results of Operations (Unaudited) (Tables)

12 Months Ended

Dec. 31, 2011

Quarterly Financial Information Disclosure [Abstract]

Schedule of Quarterly Financial Information [Table Text Block]

Quarterly data for the years ended December 31, 2011 and 2010, consisted of the following (in thousands, except per share amounts):



	Quarter Ended
	March 31		June 30		September 30			December 31

2011

Net sales	$	86,631	$	91,249	$	90,477		$	91,092
Gross profit	39,785		42,484		41,054			42,145
Income from operations	10,210		10,847		6,507			5,626
Income tax expense	3,159		3,746		2,120			806
Net income	6,639		6,872		4,563			4,970
Basic earnings per common share	0.19		0.19		0.11			0.12
Diluted earnings per common share	0.18		0.18		0.11			0.12

2010

Net sales	$	67,432	$	74,948	$	73,172		$	81,203
Gross profit	28,435		32,458		31,247			36,358
Income (loss) from operations	6,346		8,777		(3,442		)	5,523
Income tax expense (benefit)	1,822		3,124		(1,539		)	921
Net income (loss)	4,508		5,715		(1,973		)	4,210
Basic earnings (loss) per common share	0.13		0.16		(0.06		)	0.12
Diluted earnings (loss) per common share	0.13		0.16		(0.06		)	0.12

Fair Value Measurements Fair Value Measuements (Tables)

12 Months Ended

Dec. 31, 2011

Fair Value Disclosures [Abstract]

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]

Our financial assets and liabilities carried at fair value measured on a recurring basis as of December 31, 2011 and 2010, consisted of the following (in thousands):

Fair Value Measurements Using

Total Fair

Quoted prices in

Significant other

Significant

Value at

active markets

observable inputs

Unobservable inputs

Description

December 31, 2011

(Level 1)

(Level 2)

(Level 3)

Marketable securities (1)

2,798

—

Fair Value Measurements Using

Total Fair

Quoted prices in

Significant other

Significant

Value at

active markets

observable inputs

Unobservable inputs

Description

December 31, 2010

(Level 1)

(Level 2)

(Level 3)

Interest rate swap (2)

1,159

—

1,159

—

Finacial Statement Schedule Allowance For Uncollectible Accounts (Tables)

12 Months Ended

Dec. 31, 2011

Valuation and Qualifying Accounts Disclosure [Line Items]

Schedule of Valuation Allowance for Impairment of Recognized Servicing Assets [Table Text Block]



Description	Balance at Beginning of Year			Additions Charged to Costs and Expenses (a)			Deduction (b)		Balance at End of Year

ALLOWANCE FOR UNCOLLECTIBLE ACCOUNTS:

2009	$	(505	)	$	(214	)	$	178	$	(541	)
2010	(541		)	(193		)	141		(593		)
2011	(593		)	(12		)	141		(464		)

(a) We record a bad debt provision based upon historical experience and a review of individual customer balances.

(b) When an individual customer balance becomes impaired and is deemed uncollectible a deduction is made against the allowance for uncollectible accounts.

Years Ended December 31, 2011, 2010 and 2009

(In thousands)



Description	Balance at Beginning of Year	Additions Charged to Costs and Expenses (c)		Deduction	Balance at End of Year

TAX VALUATION ALLOWANCE:

2009	—	—		—	—
2010	—	—		—	—
2011	—	(361	)	—	(361	)

(c) We record a valuation allowance against a deferred tax asset when it is determined that it is more likely than not that the deferred tax asset will not be realized.

Organization And Summary Of Significant Accounting Policies Organization And Sumarry Of Significant Accounting Policies (Details) (USD $)	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated Other Comprehensive Income Loss Available for Sale Securities Excluding Tax	$ 180,000
Other Comprehensive Income (Loss), Available-for-sale Securities, Tax	115,000
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax	(30,000)	152,000
Accumulated Other Comprehensive Income (Loss), Cumulative Changes in Net Gain (Loss) from Cash Flow Hedges, Effect Net of Tax		708,000
Accumulated Other Comprehensive Income Loss Tax On Interest Rate Swap	451,000	451,000
Property, Plant and Equipment [Line Items]
Depreciation	$ 13,200,000	$ 11,400,000	$ 10,000,000
Building [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life, Average	40
Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life, Minimum	4
Property, Plant and Equipment, Useful Life, Maximum	20
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life, Minimum	3
Property, Plant and Equipment, Useful Life, Maximum	10
Land Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life, Minimum	10
Property, Plant and Equipment, Useful Life, Maximum	20
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life, Minimum	4
Property, Plant and Equipment, Useful Life, Maximum	25

Organization And Summary Of Significant Accounting Policies Goodwill And Intangible Assets (Details)	12 Months Ended
	Dec. 31, 2011
Customer Lists [Member]
Indefinite-lived Intangible Assets by Major Class [Line Items]
Finite-Lived Intangible Assets, Useful Life, Minimum	5
Finite-Lived Intangible Assets, Useful Life, Maximum	15
Developed Technology Rights [Member]
Indefinite-lived Intangible Assets by Major Class [Line Items]
Finite-Lived Intangible Assets, Useful Life, Minimum	5
Finite-Lived Intangible Assets, Useful Life, Maximum	15
Distribution Rights [Member]
Indefinite-lived Intangible Assets by Major Class [Line Items]
Finite-Lived Intangible Assets, Useful Life, Minimum	5
Finite-Lived Intangible Assets, Useful Life, Maximum	11
Licensing Agreements [Member]
Indefinite-lived Intangible Assets by Major Class [Line Items]
Finite-Lived Intangible Assets, Useful Life, Minimum	5
Finite-Lived Intangible Assets, Useful Life, Maximum	15
Noncompete Agreements [Member]
Indefinite-lived Intangible Assets by Major Class [Line Items]
Finite-Lived Intangible Assets, Useful Life, Minimum	3
Finite-Lived Intangible Assets, Useful Life, Maximum	10
Patents [Member]
Indefinite-lived Intangible Assets by Major Class [Line Items]
Finite-Lived Intangible Assets, Average Useful Life	17
Royalty Agreements [Member]
Indefinite-lived Intangible Assets by Major Class [Line Items]
Finite-Lived Intangible Assets, Average Useful Life	5

Organization And Summary Of Significant Accounting Policies Deferred Compensation (Details) (USD $)	Dec. 31, 2011	Dec. 31, 2010
Accounting Policies [Abstract]
Cash Surrender Value of Life Insurance	$ 4,800,000	$ 4,300,000
Deferred Compensation Liability, Classified, Noncurrent	$ 4,585,000	$ 4,258,000

- Definition

Carrying amount as of the balance sheet date of amounts which could be received based on the terms of the insurance contract upon surrendering life policies owned by the entity.

+ References+ Details

Organization And Summary Of Significant Accounting Policies Marketable Securities (Details) (USD $)	Dec. 31, 2011	Dec. 31, 2010
Accounting Policies [Abstract]
Available-for-sale Securities, Amortized Cost Basis	$ 2,500,000
Marketable Securities, Noncurrent	2,798,000	0
Available-for-sale Securities, Gross Unrealized Gains	$ 295,000

- Definition

This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.

+ References+ Details

- Definition

This item represents the gross unrealized gains for securities, at a point in time, which are categorized neither as held-to-maturity nor trading securities.

+ References+ Details

Organization And Summary Of Significant Accounting Policies Concentration of Credit Risk (Details)	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Accounting Policies [Abstract]
Concentration Risk, Percentage	4.00%	4.00%	6.00%

Organization And Summary Of Significant Accounting Policies Stock Based Compensation (Details) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Accounting Policies [Abstract]
Allocated Share-based Compensation Expense	$ 1,644	$ 1,294	$ 1,182

- Definition

Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.

+ References+ Details

Acquisitions Acquisitions (Details) (USD $)	3 Months Ended								12 Months Ended									12 Months Ended					12 Months Ended				12 Months Ended					12 Months Ended		12 Months Ended		12 Months Ended							12 Months Ended			12 Months Ended				12 Months Ended		12 Months Ended
Acquisitions Acquisitions (Details) (USD $)	Dec. 31, 2011	Sep. 30, 2011	Jun. 30, 2011	Mar. 31, 2011	Dec. 31, 2010	Sep. 30, 2010	Jun. 30, 2010	Mar. 31, 2010	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2011 BioSphere [Member]	Dec. 31, 2010 BioSphere [Member]	Dec. 31, 2009 BioSphere [Member]	Dec. 31, 2011 Ash [Member]	Dec. 31, 2011 Support Guide Catheter Technology [Member]	Dec. 31, 2011 Introducer Sheath Technology [Member]	Dec. 31, 2010 Manufacturing And Technology License Agreement [Member]	Sep. 30, 2011 Manufacturing And Technology License Agreement [Member]	Nov. 30, 2010 Manufacturing And Technology License Agreement [Member]	May 31, 2010 Manufacturing And Technology License Agreement [Member]	Feb. 28, 2010 Manufacturing And Technology License Agreement [Member]	Dec. 31, 2011 Vysera Biomedical Limited [Member]	Dec. 31, 2009 Vysera Biomedical Limited [Member]	Sep. 30, 2011 Vysera Valve Technology [Member]	Jun. 30, 2011 Vysera Valve Technology [Member]	Dec. 31, 2009 Hatch Medical [Member]	Dec. 31, 2009 Alveolus [Member]	Dec. 31, 2009 Biosearch [Member]	Jun. 30, 2009 Biosearch [Member]	Mar. 31, 2009 Biosearch [Member]	Dec. 31, 2010 Developed Technology Rights [Member] BioSphere [Member]	Dec. 31, 2011 Developed Technology Rights [Member] BioSphere [Member]	Dec. 31, 2011 Developed Technology Rights [Member] Ash [Member]	Dec. 31, 2011 Developed Technology Rights [Member] Manufacturing And Technology License Agreement [Member]	Dec. 31, 2009 Developed Technology Rights [Member] Vysera Biomedical Limited [Member]	Dec. 31, 2011 Developed Technology Rights [Member] Vysera Valve Technology [Member]	Dec. 31, 2009 Developed Technology Rights [Member] Hatch Medical [Member]	Dec. 31, 2009 Developed Technology Rights [Member] Alveolus [Member]	Dec. 31, 2009 Developed Technology Rights [Member] Biosearch [Member]	Dec. 31, 2010 Customer Lists [Member] BioSphere [Member]	Dec. 31, 2011 Customer Lists [Member] BioSphere [Member]	Dec. 31, 2011 Customer Lists [Member] Ash [Member]	Dec. 31, 2010 Customer Lists [Member] BioSphere Sales Distributor Agreements [Member]	Dec. 31, 2009 Customer Lists [Member] Hatch Medical [Member]	Dec. 31, 2009 Customer Lists [Member] Alveolus [Member]	Dec. 31, 2009 Customer Lists [Member] Biosearch [Member]	Dec. 31, 2010 Licensing Agreements [Member] BioSphere [Member]	Dec. 31, 2011 Licensing Agreements [Member] BioSphere [Member]	Dec. 31, 2010 Trademarks [Member] BioSphere [Member]	Dec. 31, 2011 Trademarks [Member] BioSphere [Member]	Dec. 31, 2009 Trademarks [Member] Hatch Medical [Member]	Dec. 31, 2009 Trademarks [Member] Alveolus [Member]	Dec. 31, 2009 Noncompete Agreements [Member] Hatch Medical [Member]	Dec. 31, 2009 Noncompete Agreements [Member] Biosearch [Member]	Dec. 31, 2009 Acquired in-process research and development [Member] Alveolus [Member]
Business Acquisition [Line Items]
Net Income									$ 23,044,000	$ 12,460,000	$ 22,530,000
Business Acquisition, Pro Forma Net Income (Loss)											22,470,000		7,258,000	17,000,000
Earnings Per Share, Basic	$ 0.12	$ 0.11	$ 0.19	$ 0.19	$ 0.12	$ (0.06)	$ 0.16	$ 0.13	$ 0.59	$ 0.35	$ 0.64
Business Acquisition, Pro Forma Earnings Per Share, Basic											$ 0.64		$ 0.21	$ 0.49
Earnings Per Share, Diluted	$ 0.12	$ 0.11	$ 0.18	$ 0.18	$ 0.12	$ (0.06)	$ 0.16	$ 0.13	$ 0.58	$ 0.35	$ 0.63
Business Acquisition, Pro Forma Earnings Per Share, Diluted											$ 0.63		$ 0.20	$ 0.48
Business Acquisition, Purchase Price Allocation, Current Assets, Marketable Securities												9,673,000
Business Acquisition, Purchase Price Allocation, Current Assets, Receivables												4,529,000																974,000
Business Acquisition, Purchase Price Allocation, Current Assets, Prepaid Expense and Other Assets												1,340,000																241,000
Business Acquisition, Purchase Price Allocation, Current Assets, Inventory												5,694,000																1,741,000	188,000
Business Acquisition, Purchase Price Allocation, Property, Plant and Equipment												546,000			73,000													547,000	31,000
Acquired Finite-lived Intangible Asset, Amount																																	19,000,000	3,200,000	1,000,000	1,500,000	1,000,000	8,100,000	5,700,000	380,000		7,900,000	300,000	1,300,000	590,000	1,100,000	660,000		380,000		3,200,000	650,000	1,400,000	240,000	25,000	400,000
Business Acquisition, Purchase Price Allocation, Goodwill Amount												34,016,000			2,697,000												11,420,000	8,028,000	316,000
Business Acquisition, Purchase Price Allocation, Assets Acquired											21,000,000	102,290,000			6,270,000													20,131,000	1,600,000
Business Acquisition, Purchase Price Allocation, Deferred Income Taxes, Asset (Liability), Net												16,012,000
Business Acquisition, Purchase Price Allocation, Current Liabilities, Accounts Payable												322,000																467,000
Business Acquisition, Purchase Price Allocation, Current Liabilities, Accrued Liabilities												3,617,000
Business Combinations, Purchase Price Allocation, Deferred Income Tax Liabilities												729,000
Business Combinations, Purchase Price Allocation, Unrecognized Tax Benefits												961,000
Business Acquisition, Purchase Price Allocation, Current Liabilities, Other Liabilities												936,000																572,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net															5,000,000
Business Acquisition, Purchase Price Allocation, Liabilities Assumed												6,565,000			1,270,000												0	1,039,000	0
Business Acquisition, Cost of Acquired Entity, Cash Paid												95,725,000			5,000,000	2,000,000	1,000,000		250,000	250,000	250,000	250,000			500,000	500,000	21,000,000	19,092,000	1,600,000	500,000	1,100,000
Business Combination, Acquired Receivables, Gross Contractual Amount												4,600,000																1,000,000
Research and Development Asset Acquired Other than Through Business Combination, Written-off									4,900,000														500,000					400,000
Business Acquisition, Contingent Consideration, Potential Cash Payment															1,000,000	3,000,000	1,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability																	948,000
Business Combination, Acquired Receivables, Estimated Uncollectible												51,000																49,000
Sales Revenue, Goods, Net									359,449,000	296,755,000	257,462,000		9,000,000															6,100,000	1,600,000
Business Acquisition, Pro Forma Revenue											259,914,000		317,382,000	288,589,000
Goodwill, Allocation Adjustment									(228,000)	0		228,000
Unamortized Debt Issuance Expense												522,000
Business Combination, Acquisition Related Costs									86,000				2,500,000
Royalty Revenue																											1,000,000
Net Income (Loss) Attributable to Parent	4,970,000	4,563,000	6,872,000	6,639,000	4,210,000	(1,973,000)	5,715,000	4,508,000	23,044,000	12,460,000	22,530,000																210,000	2,300,000	320,000
Investment Owned, Balance, Shares																								253,047
Other Investments																								$ 2,400,000
Acquired Finite-lived Intangible Asset, Useful Life																		10														15		15		15	10	11	15	15	10		2	10		7	8	10		15		15	15	7	7	15
Acquired Finite-lived Intangible Asset, Weighted Average Useful Life													13.6		9												3.87	3.52

Inventories Inventories (Details) (USD $) In Thousands, unless otherwise specified	Dec. 31, 2011	Dec. 31, 2010
Inventory Disclosure [Abstract]
Finished goods	$ 38,095	$ 30,780
Work-in-process	6,047	7,012
Raw materials	25,769	22,805
Total	$ 69,911	$ 60,597

Goodwill and Intangible Assets Schedule of Goodwill (Details) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010
Goodwill [Line Items]
Goodwill balance at January 1	$ 58,675	$ 33,002
Goodwill Impairment Charge	0	(8,343)
Goodwill, Allocation Adjustment	(228)	0
Additions as the result of acquisitions	2,697	34,016
Goodwill balance at December 31	$ 61,144	$ 58,675

- Definition

Carrying amount as of the balance sheet date, which is the cumulative amount paid and (if applicable) the fair value of any noncontrolling interest in the acquiree, adjusted for any amortization recognized prior to the adoption of any changes in generally accepted accounting principles (as applicable) and for any impairment charges, in excess of the fair value of net assets acquired in one or more business combination transactions.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 142

-Paragraph 45

-Subparagraph e

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 142

-Paragraph 43

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141R

-Paragraph 68

-Subparagraph l

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6905597&loc=d3e13816-109267

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141R

-Paragraph 72

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 142

-Paragraph 45

-Subparagraph e

-Clause 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141R

-Paragraph 34

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

- Definition

The aggregate amount of goodwill acquired in the period and allocated to the reportable segment. The value is stated at fair value based on the purchase price allocation.

+ References+ Details

Goodwill and Intangible Assets Finite-Lived Intangible Assets by Major Class (Details) (USD $) In Thousands, unless otherwise specified	Dec. 31, 2011	Dec. 31, 2010
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 31,469	$ 29,606
Finite-Lived Intangible Assets, Accumulated Amortization	(10,215)	(6,695)
Intangible Assets, Net (Excluding Goodwill)	21,254	22,911
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	6,455	4,631
Finite-Lived Intangible Assets, Accumulated Amortization	(1,704)	(1,445)
Intangible Assets, Net (Excluding Goodwill)	4,751	3,186
Distribution Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	2,426	2,426
Finite-Lived Intangible Assets, Accumulated Amortization	(900)	(641)
Intangible Assets, Net (Excluding Goodwill)	1,526	1,785
Licensing Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	1,983	1,833
Finite-Lived Intangible Assets, Accumulated Amortization	(436)	(352)
Intangible Assets, Net (Excluding Goodwill)	1,547	1,481
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	5,746	5,761
Finite-Lived Intangible Assets, Accumulated Amortization	(1,014)	(636)
Intangible Assets, Net (Excluding Goodwill)	4,732	5,125
Acquired in-process research and development [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross		400
Finite-Lived Intangible Assets, Accumulated Amortization		0
Intangible Assets, Net (Excluding Goodwill)		400
Noncompete Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	315	315
Finite-Lived Intangible Assets, Accumulated Amortization	(108)	(67)
Intangible Assets, Net (Excluding Goodwill)	207	248
Customer Lists [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	14,277	13,973
Finite-Lived Intangible Assets, Accumulated Amortization	(5,786)	(3,287)
Intangible Assets, Net (Excluding Goodwill)	8,491	10,686
Royalty Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	267	267
Finite-Lived Intangible Assets, Accumulated Amortization	(267)	(267)
Intangible Assets, Net (Excluding Goodwill)	$ 0	$ 0

Goodwill and Intangible Assets Schedule of Finite-Lived Assets Future Amortization Expense (Details) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2011
Finite-Lived Intangible Assets [Line Items]
2012	$ 5,767
2013	5,550
2014	5,090
2015	4,818
2016	$ 4,811

Goodwill and Intangible Assets Goodwill and Intangible Assets Text (Details) (USD $)	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Goodwill [Line Items]
Goodwill Impairment Charge	$ 0	$ (8,343,000)
Finite-Lived Intangible Assets, Amortization Expense	6,000,000	3,500,000	2,300,000
Deferred Tax Assets, Other		3,200,000
Goodwill, Impaired, Accumulated Impairment Loss	$ 8,343,000	$ 8,343,000

Income Taxes Schedule of Income before Income Tax, Domestic and Foreign (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended								12 Months Ended
	Dec. 31, 2011	Sep. 30, 2011	Jun. 30, 2011	Mar. 31, 2011	Dec. 31, 2010	Sep. 30, 2010	Jun. 30, 2010	Mar. 31, 2010	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Income Tax Disclosure [Abstract]
Domestic									$ 21,123	$ 10,551	$ 26,918
Foreign									11,752	6,237	6,176
INCOME BEFORE INCOME TAXES	$ 5,626	$ 6,507	$ 10,847	$ 10,210	$ 5,523	$ (3,442)	$ 8,777	$ 6,346	$ 32,875	$ 16,788	$ 33,094

Income Taxes Schedule of Components of Income Tax Expense (Benefit) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended								12 Months Ended
	Dec. 31, 2011	Sep. 30, 2011	Jun. 30, 2011	Mar. 31, 2011	Dec. 31, 2010	Sep. 30, 2010	Jun. 30, 2010	Mar. 31, 2010	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Income Tax Disclosure [Abstract]
Federal									$ 5,662	$ 3,547	$ 7,846
State									1,001	595	689
Foreign									1,491	740	238
Total current expense:									8,154	4,882	8,773
Federal									1,121	30	1,264
State									74	(545)	227
Foreign									482	(39)	300
Total deferred expense (benefit):									1,677	(554)	1,791
Total	$ 806	$ 2,120	$ 3,746	$ 3,159	$ 921	$ (1,539)	$ 3,124	$ 1,822	$ 9,831	$ 4,328	$ 10,564

Income Taxes Schedule of Effective Income Tax Rate Reconcilation (Details) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Income Tax Disclosure [Abstract]
Computed federal income tax expense at statutory rate of 35%	$ 11,506	$ 5,876	$ 11,583
State income taxes	699	33	596
Tax credits	(778)	(530)	(670)
Production activity deduction	(425)	(355)	(215)
Foreign tax rate differential	(1,297)	(1,212)	(1,062)
Uncertain tax positions	281	(372)	114
Deferred compensation insurance assets	88	(133)	(196)
Transaction-related expenses	0	323	0
Other — including the effect of graduated rates	(243)	698	414
Total income tax expense	$ 9,831	$ 4,328	$ 10,564

Income Taxes Schedule of Deferred Tax Assets and Liabilities (Details) (USD $) In Thousands, unless otherwise specified	Dec. 31, 2011	Dec. 31, 2010
Income Tax Disclosure [Abstract]
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Returns and Allowances	$ 188	$ 242
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation	3,064	3,230
Deferred Tax Assets, Inventory	364	1,796
Deferred Tax Assets, Operating Loss Carryforwards	22,689	26,273
Deferred Tax Assets, Deferred Income	273	214
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost	2,166	1,923
Deferred Income Tax Asset Uncertain Tax Positions	1,052	577
Deferred Tax Assets, Other	1,848	1,686
Deferred Tax Assets, Gross	31,644	35,941
Deferred Tax Liabilities, Deferred Expense	(823)	(493)
Deferred Tax Liabilities, Property, Plant and Equipment	(17,236)	(18,103)
Deferred Tax Liabilities, Goodwill and Intangible Assets, Intangible Assets	(6,169)	(9,320)
Deferred Tax Liabilities, Other	(97)	(505)
Deferred Tax Liabilities	(24,325)	(28,421)
Valuation Allowance, Amount	(361)
Deferred Tax Assets (Liabilities), Net	6,958	7,520
Deferred Tax Assets, Net, Current	3,704	4,647
Deferred Tax Assets, Net, Noncurrent	5,366	4,140
Deferred Tax Liabilities, Noncurrent	$ (2,112)	$ (1,267)

Income Taxes Summary of Income Tax Contingencies (Details) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Income Tax Disclosure [Abstract]
Unrecognized tax benefits, balance January 1	$ 2,952	$ 2,790	$ 2,668
Gross increases in tax positions taken in a prior year	347	518	163
Gross decreases in tax positions taken in a prior year	0	(51)	(40)
Gross increases in tax positions taken in the current year	865	520	710
Settlements with taxing authorities	(507)	0	0
Lapse of applicable statute of limitations	(544)	(825)	(711)
Unrecognized tax benefits, balance December 31	$ 3,113	$ 2,952	$ 2,790

Income Taxes U.S. Federal Net Operating Loss (Details) (USD $)	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010
Operating Loss Carryforwards [Line Items]
Deferred Tax Assets, Operating Loss Carryforwards, Domestic	$ 64,600,000	$ 72,400,000
Net Operating Loss Carryforwards Utilization	15
Deferred Tax Assets, Operating Loss Carryforwards, Foreign	250,000	2,800,000
Net Operating Loss Carryforwards Used In The Current Period	8,600,000	2,600,000
Net Operating Loss Carryforwards Used in The Current Period Foreign	$ 2,600,000

- Definition

The tax effect as of the balance sheet date of the amount of excess of tax deductions over gross income in a year which cannot be used on the tax return of the country of domicile in the current year but can be carried forward to reduce taxable income or income taxes payable in a future year, for which there must be sufficient tax-basis income to utilize a portion or all of the carryforward amount to realize the deferred tax asset.

+ References+ Details

- Definition

The tax effect as of the balance sheet date of the amount of excess of tax deductions over gross income in a year which cannot be used on the tax return of a country outside the country of domicile in the current year but can be carried forward to reduce taxable income or income taxes payable in a future year, for which there must be sufficient tax-basis income to utilize a portion or all of the carryforward amount to realize the deferred tax asset.

+ References+ Details

Income Taxes Unrecognized Tax Benefit (Details) (USD $)	12 Months Ended
Income Taxes Unrecognized Tax Benefit (Details) (USD $)	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Income Tax Contingency [Line Items]
Unrecognized Tax Benefits Gross Including Interest and Penalties	$ 3,500,000	$ 3,500,000
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	2,400,000	2,900,000
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued	376,000	651,000
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense	$ 12,000	$ 400,000	$ 9,000

- Definition

This element represents the total of accruals as of the date of the statement of financial position for interest recognized for an underpayment of income taxes computed by applying the applicable statutory rate of interest to the difference between a tax position recognized for financial reporting purposes and the amount previously taken or expected to be taken in a tax return of the entity and the amount of statutory penalties for a tax position claimed or expected to be claimed by the entity, in its tax return, that does not meet the minimum statutory threshold to avoid payment of penalties.

+ References+ Details

- Definition

This element represents the total of interest expense recognized for an underpayment of income taxes computed by applying the applicable statutory rate of interest to the difference between a tax position recognized for financial reporting purposes and the amount previously taken or expected to be taken in a tax return of the entity and the amount of statutory penalties in the period in which the entity claims or expects to claim a tax position, in its tax return, that does not meet the minimum statutory threshold to avoid payment of penalties.

+ References+ Details

Accrued Expenses Accrued Expenses (Details) (USD $) In Thousands, unless otherwise specified	Dec. 31, 2011	Dec. 31, 2010
Payables and Accruals [Abstract]
Payroll taxes	$ 1,786	$ 1,234
Payroll	2,075	3,708
Bonuses	2,736	2,387
Commissions	912	818
Vacation	4,362	3,792
Royalties	1,310	1,104
Value-Added Tax	1,018	874
Other Accrued Liabilities, Current	5,998	4,973
Total	$ 20,197	$ 18,890

Revolving Credit Facility and Long-Term Debt Revolving Credit Facility and Long-Term Debt (Details) (USD $) In Millions, unless otherwise specified									12 Months Ended
	Dec. 31, 2011 Wells Fargo Credit Agreement [Member]	Dec. 31, 2011 Wells Fargo Credit Agreement [Member] Fixed 30 Day Interest Rate 1 [Member]	Dec. 31, 2010 Wells Fargo Credit Agreement [Member] Fixed 30 Day Interest Rate 1 [Member]	Dec. 31, 2011 Wells Fargo Credit Agreement [Member] Fixed 30 Day Interest Rate 2 [Member]	Dec. 31, 2011 Wells Fargo Credit Agreement [Member] Swingline Variable Interest Rate [Member]	Dec. 31, 2010 Wells Fargo Credit Agreement [Member] Swingline Variable Interest Rate [Member]	Dec. 31, 2009 Wells Fargo Credit Agreement [Member] Fixed Interest Rate Swap Agreement [Member]	Dec. 31, 2010 Bank of America Line Of Credit [Member]	Dec. 31, 2011 Line of Credit [Member] Wells Fargo Credit Agreement [Member] Borrower's Option 1 [Member]	Dec. 31, 2011 Line of Credit [Member] Wells Fargo Credit Agreement [Member] Borrower's Option 2 [Member]	Dec. 31, 2011 Line of Credit [Member] Wells Fargo Credit Agreement [Member] Borrower's Option 3 [Member]	Dec. 31, 2011 Line of Credit [Member] Wells Fargo Credit Agreement [Member] Default Option [Member]	Dec. 31, 2011 Line of Credit [Member] Wells Fargo Credit Agreement [Member] Base Rate Option 1 [Member]	Dec. 31, 2011 Line of Credit [Member] Wells Fargo Credit Agreement [Member] Base Rate Option 2 [Member]	Dec. 31, 2011 Line of Credit [Member] Wells Fargo Credit Agreement [Member] Base Rate Option 3 [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	$ 125.0							$ 30.0
Debt Instrument, Basis Spread on Variable Rate									0.25%	1.25%	1.25%	1.25%		0.50%	1.00%
Debt Instrument, Description of Variable Rate Basis									base rate	London Inter-Bank Offered Rate (“LIBOR”) Market Index Rate	LIBOR Rate	LIBOR Market Index Rate	prime rate (as announced by Wells Fargo)	federal funds rate	LIBOR for an interest period of one month
Line of Credit Facility, Amount Outstanding	30.7	24.0	22.0	5.0	1.7	4.5	55.0
Line of Credit Facility, Remaining Borrowing Capacity	$ 94.3
Debt Instrument, Interest Rate, Stated Percentage		1.54%	1.52%	1.55%	1.84%	1.56%	2.73%

Derivatives Foreign Currency Forward Contracts (Details) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Derivatives, Fair Value [Line Items]
Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments	$ 221	$ 126	$ 83
30 Day Forward Contract EURO [Member]
Derivatives, Fair Value [Line Items]
Derivative, Currency Bought	12	658
30 Day Forward Contract GBP [Member]
Derivatives, Fair Value [Line Items]
Derivative, Currency Bought	328	222

Derivatives Interest Rate Swap (Details) (USD $)	12 Months Ended
Derivatives Interest Rate Swap (Details) (USD $)	Dec. 31, 2011	Dec. 31, 2010	Oct. 25, 2010
Derivative Instruments, Gain (Loss) [Line Items]
First Portion Variable-Rate Debt Outstanding		$ 55,000,000
Notional Amount of Interest Rate Cash Flow Hedge Derivatives			55,000,000
Derivative, Fixed Interest Rate	2.73%
Interest Rate Cash Flow Hedge Asset at Fair Value		1,159,000
Accumulated Other Comprehensive Income Loss Tax On Interest Rate Swap	451,000	451,000
Derivative, Cash Received on Hedge	28,000
Gain from Components Excluded from Assessment of Cash Flow Hedge Effectiveness	$ 73,000	$ 20,000

Commitments and Contingencies Schedule of Future Minimum Rental Payments for Operating Leases (Details) (USD $) In Thousands, unless otherwise specified	Dec. 31, 2011
Commitments and Contingencies Disclosure [Abstract]
Total minimum lease payments	$ 19,378

- Definition

The total of future contractually required payments on leases defined as operating.

+ References+ Details

Commitments and Contingencies Commitments and Contigenties Details (Details) (USD $)	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Commitments and Contingencies Disclosure [Abstract]
Operating Leases, Rent Expense	$ 4,100,000	$ 3,700,000	$ 2,800,000
Letters of Credit Outstanding, Amount	88,000
Irish Grants Related to Reasearch and Development, Training and Hiring	261,000	40,000	177,000
Deferred Credits and Other Liabilities	2,000,000	1,800,000
Irish Grants Related to Purchased Property Plant and Equipment	106,000	111,000	120,000
Refundable Irish Grants if Operations Cease	$ 500,000
FDA Warning Letter Unfavorable Regulatory Action [Member]
Loss Contingencies [Line Items]
Loss Contingency, Range Of Possible Revenue Loss, Maximum, Percent	1.00%

Earnings Per Common Share (EPS) Earning Per Common Share (Details) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended								12 Months Ended
	Dec. 31, 2011	Sep. 30, 2011	Jun. 30, 2011	Mar. 31, 2011	Dec. 31, 2010	Sep. 30, 2010	Jun. 30, 2010	Mar. 31, 2010	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount									909	878	681
Net Income (Loss) Attributable to Parent	$ 4,970	$ 4,563	$ 6,872	$ 6,639	$ 4,210	$ (1,973)	$ 5,715	$ 4,508	$ 23,044	$ 12,460	$ 22,530
Weighted Average Number of Shares Outstanding, Basic									39,086	35,290	35,014
Earnings Per Share, Basic	$ 0.12	$ 0.11	$ 0.19	$ 0.19	$ 0.12	$ (0.06)	$ 0.16	$ 0.13	$ 0.59	$ 0.35	$ 0.64
Effect of dilutive stock options and warrants									647	686	744
Net Income (Loss) Available to Common Stockholders, Diluted									$ 23,044	$ 12,460	$ 22,530
Weighted Average Number of Shares Outstanding, Diluted									39,733	35,976	35,758
Earnings Per Share, Diluted	$ 0.12	$ 0.11	$ 0.18	$ 0.18	$ 0.12	$ (0.06)	$ 0.16	$ 0.13	$ 0.58	$ 0.35	$ 0.63

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 13, 14

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 171

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 40

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Diluted Earnings Per Share

-URI http://asc.fasb.org/extlink&oid=6510752

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Contingent Stock Agreement

-URI http://asc.fasb.org/extlink&oid=6508534

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Antidilution

-URI http://asc.fasb.org/extlink&oid=6505113

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 07-4

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 07-4

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 36, 37, 38

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 03

-Paragraph 20

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 7

-Paragraph 18

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6920599&loc=d3e1252-109256

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=6945512&loc=d3e4984-109258

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.23)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e565-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A7

-Appendix A

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 87-21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 10, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28, 29, 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 03

-Paragraph 19

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

- Definition

The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.

+ References+ Details

- Definition

Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 171

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 40

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=6920599&loc=d3e1448-109256

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Weighted-Average Number of Common Shares Outstanding

-URI http://asc.fasb.org/extlink&oid=6528421

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 07-4

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Employee Stock Purchase Plan Stock Options and Warrants Schedule of Employee Service-based Compensation, Allocation of Recognized Period Costs, by Report Line (Details) (USD $)	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Cost of Goods Sold	$ 193,981,000	$ 168,257,000	$ 148,660,000
Research and Development Expense	21,938,000	15,335,000	11,168,000
Selling, General and Administrative Expense	104,502,000	87,615,000	64,787,000
Allocated Share-based Compensation Expense	1,644,000	1,294,000	1,182,000
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized	5,900,000
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition	3.6
Cost of Sales [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Cost of Goods Sold	241,000	201,000	205,000
Research and Development Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Research and Development Expense	86,000	56,000	57,000
Selling General And Administrative Stock Based Compensation Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Selling, General and Administrative Expense	$ 1,317,000	$ 1,037,000	$ 920,000

- Definition

+ References+ Details

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References+ Details

- Definition

The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.

+ References+ Details

Employee Stock Purchase Plan Stock Options and Warrants Stock Option Activity (Details) (USD $) In Thousands, except Per Share data, unless otherwise specified	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Total Intrinsic Value	$ 9,433	$ 1,928	$ 2,757
Employee Service Share-based Compensation, Cash Received from Exercise of Stock Options	7,197	1,330	1,690
Employee Service Share-based Compensation, Tax Benefit Realized from Exercise of Stock Options	3,122	399	987
Stock Option Activity [Rollforward]
Stock Options Outstanding, Beginning of Period	4,389
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	844	125	175
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	(1,099)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period	(57)
Stock Options Outstanding, End of Period	4,077	4,389
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	2,744
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	4,049
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 11.96	$ 10.56
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price	$ 13.75
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price	$ 7.69
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price	$ 13
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 11.43
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price	$ 11.95
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	3.5
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value	7,877
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	2.5
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value	7,090
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term	3.5
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 5.28	$ 5.64	$ 5.49
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value	$ 7,871

Employee Stock Purchase Plan Stock Options and Warrants Stock Based Compensation Plans (Details) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2011
Long Term Incentive Plan 2006 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Option Vesting Performance Based	1
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	1,400
Employee Stock Purchase Plan Qualified [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	281
Share Based Compensation Arragement Employee Stock Purchase Plan Percentage of Market Price Purchase Date	95.00%
Employee Stock Purchase Plan Non Qualified [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	79
Minimum [Member] \| Long Term Incentive Plan 2006 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Option Vesting	3
Stock Option Contractual Life	7
Maximum [Member] \| Long Term Incentive Plan 2006 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Option Vesting	5
Stock Option Contractual Life	10

Employee Stock Purchase Plan Stock Options and Warrants Stock Based Compensation Fair Value Calculation Assumptions (Details) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum	0.68%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum	1.34%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate		2.24%	2.70%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Minimum	4.2
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Maximum	6
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term		6	6
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%	0.00%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum	42.11%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum	45.29%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate		41.40%	42.40%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	844	125	175
Fair Value Of Stock Option On Grant Date Net Of Forfeitures	$ 4,300	$ 705	$ 1,000

Employee Stock Purchase Plan Stock Options and Warrants Summary Of Options Outstanding (Details) (USD $) In Thousands, except Per Share data, unless otherwise specified	12 Months Ended
	Dec. 31, 2011
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	$ 7.65
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	$ 17.34
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options	4,077
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options	2,744
Range One [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	$ 7.65
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	$ 9.70
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options	1,021
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	1.6
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price, Beginning Balance	$ 8.74
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options	926
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price	$ 8.64
Range Two [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	$ 9.71
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	$ 11.53
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options	1,111
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	3.3
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price, Beginning Balance	$ 10.99
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options	885
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price	$ 10.85
Range Three [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	$ 12.02
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	$ 13.75
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options	1,286
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	5.5
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price, Beginning Balance	$ 13.25
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options	364
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price	$ 12.10
Range Four [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	$ 13.82
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	$ 17.34
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options	659
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	2.8
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price, Beginning Balance	$ 16.09
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options	569
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price	$ 16.45

Segment Reporting And Foreign Operations Segment Reporting (Details) (USD $) In Thousands, unless otherwise specified	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-Lived Assets	$ 179,140	$ 128,055	$ 114,646
United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-Lived Assets	134,393	97,881	89,428
Ireland [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-Lived Assets	36,008	22,203	17,148
Other Foreign Countries [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-Lived Assets	$ 8,739	$ 7,971	$ 8,070

Segment Reporting And Foreign Operations Segment Reporting Operating Income (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended								12 Months Ended
	Dec. 31, 2011	Sep. 30, 2011	Jun. 30, 2011	Mar. 31, 2011	Dec. 31, 2010	Sep. 30, 2010	Jun. 30, 2010	Mar. 31, 2010	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Segment Reporting Information [Line Items]
Revenue, Net	$ 91,092	$ 90,477	$ 91,249	$ 86,631	$ 81,203	$ 73,172	$ 74,948	$ 67,432	$ 359,449	$ 296,755	$ 257,462
Operating Expenses									132,278	111,294	75,955
Operating Expense, Excluding Goodwill Impairment Charge										102,950
Goodwill, Impairment Loss									0	8,344	0
Operating Income (Loss)									33,190	17,204	32,847
Nonoperating Income (Expense)									(315)	(416)	247
Income Tax Expense (Benefit)	806	2,120	3,746	3,159	921	(1,539)	3,124	1,822	9,831	4,328	10,564
Net Income									23,044	12,460	22,530
Cardiovascular Segment [Member]
Segment Reporting Information [Line Items]
Revenue, Net									347,430	287,707	249,800
Operating Expenses									122,600	93,884	69,097
Goodwill, Impairment Loss									0	0	0
Operating Income (Loss)									38,010	30,176	35,836
Endoscopy Segment [Member]
Segment Reporting Information [Line Items]
Revenue, Net									12,019	9,048	7,662
Operating Expenses									9,678	9,066	6,858
Goodwill, Impairment Loss									0	8,344	0
Operating Income (Loss)									$ (4,820)	$ (12,972)	$ (2,989)

- Definition

Loss recognized during the period that results from the write-down of goodwill after comparing the implied fair value of reporting unit goodwill with the carrying amount of that goodwill. Goodwill is assessed at least annually for impairment.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 142

-Paragraph 47

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 142

-Paragraph 20

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 142

-Paragraph 45

-Subparagraph e

-Clause 5

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 142

-Paragraph 43

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 2

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6905597&loc=d3e13854-109267

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13777-109266

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=6905597&loc=d3e13816-109267

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141R

-Paragraph 72

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

- Definition

The sum of the current income tax expense or benefit and the deferred income tax expense or benefit pertaining to continuing operations.

+ References+ Details

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 29

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A1, A4, A5

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 5

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4K

-URI http://asc.fasb.org/extlink&oid=6922042&loc=SL4591552-111686

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=6921628&loc=SL4569616-111683

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4J

-URI http://asc.fasb.org/extlink&oid=6922042&loc=SL4591551-111686

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1A

-Subparagraph (a),(c)

-URI http://asc.fasb.org/extlink&oid=6921930&loc=SL4573702-111684

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph c(1)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Segment Reporting And Foreign Operations Total Assets By Business Segment (Details) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Segment Reporting, Asset Reconciling Item [Line Items]
Payments to Acquire Property, Plant, and Equipment	$ 59,195	$ 23,648	$ 18,478
Depreciation, Depletion and Amortization	19,194	14,856	12,271
Assets	447,017	369,480	271,513
Cardiovascular Segment [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Payments to Acquire Property, Plant, and Equipment	58,775	23,494	18,475
Depreciation, Depletion and Amortization	18,219	13,851	11,406
Assets	434,747	355,718	249,726
Endoscopy Segment [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Payments to Acquire Property, Plant, and Equipment	420	154	3
Depreciation, Depletion and Amortization	975	1,005	865
Assets	$ 12,270	$ 13,762	$ 21,787

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References+ Details

- Definition

The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.

+ References+ Details

Segment Reporting And Foreign Operations Segment Reporting By Business Segment (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended								12 Months Ended
	Dec. 31, 2011	Sep. 30, 2011	Jun. 30, 2011	Mar. 31, 2011	Dec. 31, 2010	Sep. 30, 2010	Jun. 30, 2010	Mar. 31, 2010	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Revenue from External Customer [Line Items]
Revenue, Net	$ 91,092	$ 90,477	$ 91,249	$ 86,631	$ 81,203	$ 73,172	$ 74,948	$ 67,432	$ 359,449	$ 296,755	$ 257,462
Sales By Business Segment % Change Current Year vs Prior Year	21.00%				15.00%				21.00%	15.00%	13.00%
Stand Alone Devices [Member]
Revenue from External Customer [Line Items]
Revenue, Net									101,959	88,586	76,075
Sales By Business Segment % Change Current Year vs Prior Year	15.00%				16.00%				15.00%	16.00%	12.00%
Custom Kit And Procedures Trays [Member]
Revenue from External Customer [Line Items]
Revenue, Net									91,532	82,799	74,541
Sales By Business Segment % Change Current Year vs Prior Year	11.00%				11.00%				11.00%	11.00%	12.00%
Inflation Devices [Member]
Revenue from External Customer [Line Items]
Revenue, Net									67,353	62,495	61,058
Sales By Business Segment % Change Current Year vs Prior Year	8.00%				2.00%				8.00%	2.00%	(1.00%)
Catheters [Member]
Revenue from External Customer [Line Items]
Revenue, Net									55,357	44,824	38,126
Sales By Business Segment % Change Current Year vs Prior Year	23.00%				18.00%				23.00%	18.00%	23.00%
Embolization Devices [Member]
Revenue from External Customer [Line Items]
Revenue, Net									31,229	9,003	0
Sales By Business Segment % Change Current Year vs Prior Year	247.00%				0.00%				247.00%	0.00%	0.00%
Total Cardiovascular [Member]
Revenue from External Customer [Line Items]
Revenue, Net									347,430	287,707	249,800
Sales By Business Segment % Change Current Year vs Prior Year	21.00%				15.00%				21.00%	15.00%	10.00%
Endoscopy Devices [Member]
Revenue from External Customer [Line Items]
Revenue, Net									$ 12,019	$ 9,048	$ 7,662
Sales By Business Segment % Change Current Year vs Prior Year	33.00%				18.00%				33.00%	18.00%	0.00%

Segment Reporting And Foreign Operations Foreign Sales (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended								12 Months Ended
	Dec. 31, 2011	Sep. 30, 2011	Jun. 30, 2011	Mar. 31, 2011	Dec. 31, 2010	Sep. 30, 2010	Jun. 30, 2010	Mar. 31, 2010	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Segment Reporting Information [Line Items]
Revenue, Net	$ 91,092	$ 90,477	$ 91,249	$ 86,631	$ 81,203	$ 73,172	$ 74,948	$ 67,432	$ 359,449	$ 296,755	$ 257,462
Foreign Sales Percent of Total Sales	35.00%				32.00%				35.00%	32.00%	34.00%
Foreign Sales [Member]
Segment Reporting Information [Line Items]
Revenue, Net									$ 125,900	$ 95,200	$ 86,400

Royalty Agreements Royalty Agreements (Details) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010
Datascope Royalty Agreement [Member]
Current Royalty Rate	5.00%
Minimum Royalty Payment	$ 50
Royalty Expense	50
BioSphere APHP Royalty [Member]
Current Royalty Rate	5.00%
Future Royalty Rate	2.50%
Royalty Expense	$ 1,300	$ 401

Employee Benefit Plans Employee Benefit Plans (Details) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Defined Benefit Plan Disclosure [Line Items]
Minimum Years Of Age	18
Minimum Service Requirement	90
Defined Contribution Plan, Cost Recognized	$ 1,200	$ 1,200	$ 883
Defined Contribuition Plan Percentage Minimum Foreign Employees	3.00%
Defined Contribuition Plan Percentage Maximum Foreign Employees	36.00%
Defined Contribuition Plan Percentage Minimum Foreign Management	10.00%
Defined Contribution Plan Foreign, Cost Recognized	$ 469	$ 565	$ 550

Quarterly Results of Operations (Unaudited) Quarterly Results of Operations (Unaudited) (Details) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended								12 Months Ended
	Dec. 31, 2011	Sep. 30, 2011	Jun. 30, 2011	Mar. 31, 2011	Dec. 31, 2010	Sep. 30, 2010	Jun. 30, 2010	Mar. 31, 2010	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Quarterly Financial Information Disclosure [Abstract]
Net sales	$ 91,092	$ 90,477	$ 91,249	$ 86,631	$ 81,203	$ 73,172	$ 74,948	$ 67,432	$ 359,449	$ 296,755	$ 257,462
Gross profit	42,145	41,054	42,484	39,785	36,358	31,247	32,458	28,435	165,468	128,498	108,802
Income from operations	5,626	6,507	10,847	10,210	5,523	(3,442)	8,777	6,346	32,875	16,788	33,094
Income Tax Expense (Benefit)	806	2,120	3,746	3,159	921	(1,539)	3,124	1,822	9,831	4,328	10,564
Net income	$ 4,970	$ 4,563	$ 6,872	$ 6,639	$ 4,210	$ (1,973)	$ 5,715	$ 4,508	$ 23,044	$ 12,460	$ 22,530
Earnings Per Share, Basic	$ 0.12	$ 0.11	$ 0.19	$ 0.19	$ 0.12	$ (0.06)	$ 0.16	$ 0.13	$ 0.59	$ 0.35	$ 0.64
Earnings Per Share, Diluted	$ 0.12	$ 0.11	$ 0.18	$ 0.18	$ 0.12	$ (0.06)	$ 0.16	$ 0.13	$ 0.58	$ 0.35	$ 0.63

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

+ Details

- Definition

+ References+ Details

- Definition

The sum of the current income tax expense or benefit and the deferred income tax expense or benefit pertaining to continuing operations.

+ References+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

Fair Value Measurements Fair Value Measurements (Details) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other Asset Impairment Charges	$ 103	$ 8,500	$ 154
Available-for-sale Securities, Fair Value Disclosure	2,798
Goodwill, Impairment Loss	0	8,344	0
Interest Rate Cash Flow Hedge Asset at Fair Value		1,159
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure	2,798
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest Rate Cash Flow Hedge Asset at Fair Value		$ 1,159

- Definition

This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents Available-for-sale Securities which consist of all investments in certain debt and equity securities neither classified as trading or held-to-maturity securities. A debt security represents a creditor relationship with an enterprise. Debt securities include, among other items, US Treasury securities, US government securities, municipal securities, corporate bonds, convertible debt, commercial paper, and all securitized debt instruments. An equity security represents an ownership interest in an enterprise or the right to acquire or dispose of an ownership interest in an enterprise at fixed or determinable prices. Equity securities include, among other things, common stock, certain preferred stock, warrant rights, call options, and put options, but do not include convertible debt. An entity may opt to provide the reader with additional narrative text to better understand the nature of investments in debt and equity securities which are categorized as Available-for-sale.

+ References+ Details

- Definition

+ References

+ Details

Stockholders' Equity Stockholders' Equity (Details) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2009	Dec. 31, 2011	Apr. 30, 2007
Stockholders' Equity Note [Abstract]
Stock Issued During Period, Shares, New Issues		5,520,000
Stock Issued During Period, Value, New Issues		$ 87,700,000
Underwriting Discounts and Commissions		4,600,000
Other Indirect Cost In Connection With Public Offering		127,000
Stock Repurchase Program, Number of Shares Authorized to be Repurchased			1,400,000
Stock Repurchased During Period, Shares	250,158
Stock Repurchased During Period, Value	$ 2,500,000

- Definition

Number of new stock issued during the period.

+ References+ Details

- Definition

Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.

+ References+ Details

- Definition

Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.

+ References+ Details

- Definition

Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.

+ References+ Details

Subsequent Event Ostial Solutions Asset Purchase Agreement (Details) (USD $) In Millions, unless otherwise specified	1 Months Ended
	Jan. 31, 2012
Subsequent Event [Line Items]
Subsequent Event, Date	Jan. 31, 2012
Initial Payment Paid At Closing	$ 10.0
Anticipated Purchase Price To Be Paid Within Six Months of Closing	6.5
Maximum Additional Amount Possibly Due Based On Future Related Product Sales	$ 13.5

Finacial Statement Schedule Finacial Statement Schedule (Details) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Allowance for Doubtful Accounts [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Valuation Allowances and Reserves, Beginning Balance	$ (593)	$ (541)	$ (505)
Valuation Allowances and Reserves, Period Increase (Decrease)	(12)	(193)	(214)
Valuation Allowances and Reserves, Deductions	141	141	178
Valuation Allowances and Reserves, Ending Balance	(464)	(593)	(541)
Valuation Allowance of Deferred Tax Assets [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Valuation Allowances and Reserves, Beginning Balance	0	0	0
Valuation Allowances and Reserves, Period Increase (Decrease)	(361)	0	0
Valuation Allowances and Reserves, Deductions	0	0	0
Valuation Allowances and Reserves, Ending Balance	$ (361)	$ 0	$ 0